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Abstract 
Piglets that are fed via total parenteral nutrition (TPN) experience profound 
gut atrophy and rapid decline in splanchnic blood flow compared to enterally-fed 
piglets. Sixty percent of total nutrient intake as enteral feeding is required to sustain 
“normal” small intestinal metabolism and morphology, which is likely not feasible 
with sick neonates. Whether the potential benefit of complete or partial enteral 
nutrition is related to single or multiple nutrients is not yet fully understood. However, 
the luminal presence of specific nutritive factors such as amino acids may act as 
trophic factors for intestinal recovery during TPN or enteral re-feeding. Arginine is a 
good candidate to investigate potential trophic effects as it is involved in many 
important metabolic pathways such as nitric oxide synthesis, ureagenesis, polyamine 
synthesis and protein synthesis. TPN-induced gut atrophy reduces intestinal de novo 
synthesis of arginine in neonates which may then limit arginine availability. We 
hypothesized that delivery of a high amount of dietary arginine alone into the gut 
could induce partial recovery from TPN-induced gut atrophy in neonatal piglets, while 
improving superior mesenteric artery (SMA) blood flow. We also hypothesized that 
enteral delivery of low amounts of arginine would result in attenuated responses 
compared to the high enteral arginine. Thus, our objectives were to assess the effect of 
route of intake and dietary concentration of arginine alone on tissue protein synthesis, 
SMA blood flow and gut morphology in TPN-fed neonatal Yucatan miniature piglets 
with small-intestinal atrophy. Twenty-four piglets (14 - 17 d old) were fed complete 
TPN, containing 1.0 g arginine/kg/d until study day 4 to induce atrophy, then switched  
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to arginine-free TPN and randomized to receive a continuous intragastric infusion of 
either low arginine (0.6 g/kg/d) (IG-L Arg) (n = 6) or high arginine (1.6 g/kg/d) (IG-H 
Arg) (n = 6). A third group was randomized to receive high arginine intravenously 
(1.6 g/kg/d in TPN) (IV-H Arg) (n = 6). A group of sow-fed littermates (SF 
Reference) (n = 6) was also included. On study day 7, crypt cell proliferation and 
tissue specific protein synthesis rates were measured. This thesis demonstrated for the 
first time that the delivery of arginine alone intragastrically, irrespective of the amount 
provided, stimulated hepatic protein synthesis (P = 0.01) compared to intravenous 
delivery of arginine. SMA blood flow declined continuously during the period when 
all animals were receiving the same complete TPN. It further decreased following the 
initiation of the test diets and reached a plateau approximately 48 hours after the test 
diets were initiated. At steady state, SMA blood flow was significantly different 
among all treatment groups (P = 0.002). IV-H Arg treatment had the smallest 
reduction in blood flow (22% lower than baseline). The provision of high arginine 
enterally attenuated some of the reduction of blood flow, whereas the IG-L Arg piglets 
demonstrated the greatest reduction, at ~40% lower than baseline at study end. In 
piglets fed solely by TPN, some of the plasma indispensable amino acids were very 
high compared to the IG-H Arg piglets. Remarkably, the provision of only arginine 
into the gut resulted in a plasma profile of some of these amino acids that was very 
similar to sow-reared piglets. In spite of experiencing a greater amelioration of the 
reduction of SMA blood flow, the small intestinal morphological characteristics were 
not significantly improved compared to the other treatment groups. Although IG-H  
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Arg was not as effective as IV-H Arg in sustaining SMA blood flow, morphological 
outcomes were not significantly worse than in the IV-H Arg piglets; indeed, the small 
intestine was significantly longer in the IG-H Arg piglets compared to IV-H Arg 
group, and all other outcomes were similar among treatment groups. These results 
suggest that IG delivery of arginine was likely beneficial as a trophic factor in gut-
atrophied neonatal piglets. 
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1.0 Review of Literature 
1.1 Total Parenteral Nutrition 
Total parenteral nutrition (TPN) refers to the provision of a nutritionally complete, 
elemental formula via an intravenous route; the provision of nutrients into the 
gastrointestinal tract is known as enteral nutrition. TPN is frequently necessary for the 
nutritional management of preterm or premature neonates who cannot tolerate complete 
enteral feeding. It is common for newborn preterm infants to require short term TPN for 
nutritional support, often due to severe respiratory distress syndrome that precludes oral 
feeding (Hay 2008). Long term TPN support is sometimes required by infants born with 
congenital gastrointestinal (GI) malformations, or those who develop necrotizing 
enterocolitis (NEC) which can lead to short bowl syndrome (Quiros-Tejeira et al, 2004). 
In neonatal intensive care units, providing small amounts of enteral feeding, known as 
partial enteral nutrition, in parallel with TPN feeding is a common practice to avoid 
complications that are known to develop with prolonged TPN feeding. Partial enteral 
feeding may also be beneficial to minimise the feeding intolerance that commonly occurs 
during the re-introduction of enteral feeding. It is not yet clear whether the potential 
benefits related to partial enteral feeding are related to the overall composition of the 
nutritive substance provided, or whether a single specific nutrient is important. Therefore, 
the luminal presence of specific nutritive factors, such as amino acids, may be beneficial 
as trophic factors during TPN feeding or when enteral re-feeding is initiated.   
1.2 Amino Acids in Parenteral Nutrition 
One of the main aims of TPN support is to provide adequate but not excessive  
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amounts of indispensable amino acids to fulfill the requirement for whole body protein 
synthesis and growth. Excess amounts of indispensable amino acids or their by-products 
could stress immature metabolic systems in neonates, and thus lead to the accumulation 
of toxic end products such as ammonia. For human neonates, the amino acid profiles of 
the various commercial parenteral products currently available were devised based on the 
amino acid profiles in human milk, infant plasma or cord blood (Brunton et al, 2000).  
Ideally, the specific enteral or parenteral requirement for each indispensable 
amino acid should be determined in neonates; currently, they are not well defined. What 
is currently known about the requirements for the indispensable amino acids has been 
determined by a number of different methods in adults and to a lesser extent in children. 
In the past, nitrogen balance was used to determine individual amino acid requirements of 
adult humans (Zello et al, 1995). However, more precise metabolic approaches such as 
plasma amino acid concentrations, amino acid oxidation (AAO) and the indicator amino 
acid oxidation (IAAO) techniques were subsequently introduced to estimate amino acid 
requirements (Zello et al, 1995). The AAO technique is based on the concept that amino 
acids in excess of the amounts needed for protein synthesis are preferentially oxidized. 
An important methodological issue with AAO is that all of the excess amino acids are not 
always oxidised completely, but catabolised to other metabolic products (Zello et al, 
1995). The IAAO technique was developed to address such issues. The IAAO technique 
is based on the partitioning of a single indispensable amino acid between oxidation and 
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protein synthesis, and the balance is sensitive to the most limiting indispensable amino 
acids in the diet. The  
provision of excess amounts of the previously limiting amino acid will reduce the 
oxidation of the indicator amino acid to a low and constant level. Recently, this method 
has been adapted to be minimally invasive and has been employed to measure the 
requirement for some amino acids in parenterally-fed neonates (Bertolo et al, 1998; 
House et al, 1998). 
An important concept when considering amino acid requirements of infants is that 
requirements are not the same for the parenteral versus enteral route of feeding for many 
amino acids. Wykes et al (1992) demonstrated that plasma amino acid concentrations 
were very different in human neonates fed the same elemental formula via the two 
different routes, suggesting that a significant role is played by the splanchnic organs in 
amino acid metabolism. A series of studies in neonatal piglets has demonstrated that the 
requirements for lysine, threonine, branched-chain amino acids and methionine are 
substantially lower during TPN feeding compared to enteral feeding (House et al, 1998; 
Bertolo et al, 1998; Elango et al, 2002; Shoveller et al, 2003). The methionine, threonine 
and lysine requirements for post-surgical intravenously fed human neonates estimated by 
IAAO technique were also lower than the amounts provided in commercially available 
pediatric TPN products (Courtney-Martin et al, 2008, Chapman et al, 2009; Chapman et 
al, 2010). These studies have demonstrated the importance of considering the 
concentration of individual amino acids in the diet when the route of feeding by-passes 
the splanchnic tissues.  
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1.3 Neonatal piglet as a model for human infants 
The piglet is an appropriate animal model to investigate questions related to 
nutritional metabolism in human neonates because of similar gastrointestinal tract  
morphology, physiology and metabolic changes during development (Pond et al, 1978b). 
The gross body composition of the newborn piglet is more similar to the preterm infant 
than the term-born infant which has greater fat accretion at birth (Shulman et al, 1993). 
Piglets are also developmentally immature compared to human, term-born infants 
(Shulman et al, 1993). Therefore, the neonatal piglet is a clinically relevant model to 
study the complications associated with TPN feeding in prematurely born infants.  
The neonatal miniature piglet has not been widely used for studies of nutrient 
metabolism compared to the domestic piglet.  Shulman et al (1988) reported that the 
small intestinal mucosal enzyme activities of 6-wk-old miniature piglets were similar to 
this those found in young human infants. The mean growth rate of sow-fed Yucatan 
miniature piglets is less rapid during first month of life, compared to domestic piglets, 
growing at a rate of ~45 g/kg/d (Myrie et al, 2011) compared 79 g/kg/d (Wykes et al, 
1993). In contrast, low birth weight premature infants grew at ~20.5 g/kg/d during first 
month of their life when fed fortified human milk (Kashyap et al, 1990). Thus, studies 
using a piglet model may quickly identify nutrient deficiencies or metabolic changes 
because of the accelerated growth rate; however, the miniature pig model may represent a 
better model for nutrient metabolism in infants, growing at a rate that is only half the 
growth rate of domestic piglet and more similar to infants.  
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For the study of amino acid metabolism and requirements, there are now very 
good data to demonstrate that the piglet is an ideal model for the human infant. There has 
been a series of studies in piglets which determined specific amino acid requirements, and 
subsequent studies in human infants that confirmed the piglet  
findings. One of the first was a study to determine the optimal proportion of aromatic 
amino acids in TPN. House et al (1997a; 1997b) established the requirement and 
demonstrated that the aromatic amino acids should be provided as 59% phenylalanine and 
41% tyrosine in the neonatal piglet model. The ratio was later established in human 
infants to be 56:44 (Roberts et al, 2001). The absolute amino acid requirement values for 
human infants were also predicted from the piglet data by dividing the piglet value by 
five, to accommodate the differing growth rates. Using this correction, the similarity 
between the predicted (from piglets) and measured requirements in humans has now been 
established for threonine (Bertolo et al, 1998; Chapman et al, 2009), methionine 
(Shoveller et al, 2003; Courtney-Martin et al, 2008), and tyrosine (House et al, 1997a; 
Roberts et al, 2001). It is now clear that estimates of amino acid requirements derived 
from piglet data are transferable to human infants (Chapman et al, 2009). Unfortunately, 
the requirement for arginine, a metabolically important amino acid for the neonate, has 
not yet been determined for the human infant. An attempt was made to determine the 
arginine requirement for TPN-fed neonatal piglets using the IAAO technique. However, 
the researchers were not successful in determining a breakpoint estimate of requirement, 
likely because arginine is a conditionally indispensable amino acid for neonates, and there 
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was variability in de novo synthesis of arginine amongst the piglets (unpublished data 
from Brunton et al). 
1.4 Arginine 
Arginine is an aliphatic straight chain amino acid with a guanidine group at the 
distal end of the chain. As the guanidine group is positively charged in neutral, acidic and 
even somewhat basic environments, arginine imparts basic chemical properties.  
1.4.1 Biological importance of arginine 
Arginine is an important, abundant amino acid. It constitutes approximately 6.9% 
of total body proteins in fetal and neonatal piglets (Williams et al, 1954) and 7.7% in the 
human foetus (Widdowson et al, 1979). Arginine is also involved in the synthesis of other 
biologically important molecules such as nitric oxide (NO), creatine and polyamines. 
Arginine plays a critical role as a urea cycle metabolite, thus is important for ammonia 
detoxification (Figure 1). Two well-described pathways of arginine metabolism include 
the conversion of arginine to NO and the breakdown of arginine to urea and ornithine by 
arginase. The fate of arginine catabolism via the urea cycle or NO synthesis depends on 
the activities of the enzymes involved in the different catabolic pathways and the 
provision of substrates. As such, higher arginase activity in the liver leads to urea 
synthesis, with no release of arginine. 
Arginine is also an allosteric activator of N-acetylglutamate synthetase (NAGs) 
(Kawamoto et al, 1982). NAGs catalyses the synthesis of N-acetylglutamate from L-
glutamate and acetyl CoA in mitochondria of liver cells. The N-acetylglutamate is an 
allosteric activator of carbamoyl phosphate synthetase-1 (CPS-1) in the liver of ureotelic 
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animals (Kawamoto et al, 1982). The CPS-1 is the first enzyme in the urea cycle that 
converts ammonia and bicarbonate into carbamoyl phosphate which is the substrate for 
ornithine transcarbamylase (OTC). Therefore arginine is an activator of the urea cycle by 
a mechanism other than as a direct intermediary amino acid in the urea cycle.  
Nitric oxide is an end product of arginine metabolism whereby arginine is 
converted into citrulline and nitric oxide. NO acts as a vasodilator which modulates  
blood pressure and thus blood flow. NO also acts as a neurotransmitter and mediator of 
the immune response (Homer & Wanstall, 2000). The amount of arginine utilised for NO 
synthesis accounts for only 0.6 µmol arginine/kg/h in young adults (Castillo et al, 1994). 
Although the fractions of whole body arginine flux associated with urea (15%) and NO 
synthesis (1.2%) in healthy humans are small, arginine leaving the plasma compartment 
serves as a major precursor pool (54%) for whole body daily NO synthesis (Castillo et al, 
1996). Currently, there are no data available for neonates to describe the proportion of 
arginine flux dedicated to the various metabolic pathways.  
Arginine is also a precursor of ornithine, which is the amino acid precursor for polyamine 
synthesis. Polyamines (putrescine, spermidine and spermine) regulate gene expression, 
DNA and protein syntheses, apoptosis, cell proliferation and differentiation, and thus are 
essential for growth and differentiation of cells in many tissues including intestinal 
epithelial cells (Johnson, 1988; Blachier et al, 1995). It is accepted that highly 
proliferative cells such as gastrointestinal tissues in growing animals demand higher 
amounts of polyamines.  
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Recently, it has been suggested that de novo creatine synthesis places a significant 
demand on arginine partitioning (Brosnan et al, 2009). Creatine and creatine phosphate 
function as buffers for ATP synthesis in tissues with high energy demand. They also 
serve as an energy shuttle between the sites of ATP synthesis and ATP utilization (Wyss 
& Kaddurah-Daouk, 2000). However, once again, the proportion of arginine flux required 
to meet the demands for creatine synthesis has not yet been empirically determined in 
human infants.   
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Figure 1.1: Metabolic pathway of arginine  Bertolo & Burrin, 2008 
This figure represents arginine metabolism in adult human (Small intestinal-renal axis).  
Abbreviations in the figure indicate enzymes as; ASL: argininosuccinate lyase; ASS: 
argininosuccinate synthetase; CPS-I: carbamoyl phosphate synthetase; OAT: ornithine 
aminotransferase; OTC: ornithine transcarbamoylase; P5C: pyrroline-5-carboxylate; P5CDH: 
pyrroline-5-carboxylate dehydrogenase. P5C synthase does not occur in adult human liver while 
the functional urea cycle occurs only in liver. OTC expressed widely in small intestine while ASS 
and ASL expressed widely in kidney. 
 
 
In summary, arginine is a metabolically important amino acid for neonates during 
the rapid growth period, and recently, the consequences of limited arginine availability 
have captured the attention of clinicians and researchers.  
1.4.2 General arginine metabolism 
1.4.2.1 Arginine de novo synthesis 
a. De novo arginine synthesis in adults 
According to studies in vitro, proline, glutamate and glutamine in adults are 
effectively converted into citrulline in the small intestine as the activities of pyrroline-5-
carboxylate synthase (P5CS) (Jones, 1985), ornithine aminotransferase (OAT), CPS-1 
and OTC  are relatively high in intestinal mucosal tissues (Wu, 1998) (Figure 1). 
However, a recent study by Marini et al (2010) demonstrated that the dietary glutamine 
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and proline made only a minor contribution to the synthesis of citrulline in mice, even 
when the mice were fed an arginine-free diet. The extraction of plasma arginine and 
ornithine by the small intestine was adequate to support citrulline synthesis during the 
arginine-free diet feeding. In another study in mice, using multiple isotope tracers, 
Marinin et al (2012) showed that dietary and plasma arginine were the main precursors 
for citrulline synthesis in the gut during feeding and feed-deprivation respectively (Marini 
et al, 2012). Low intestinal activities of argininosuccinate synthetase (ASS) and 
argininosuccinate lyase (ASL), and higher activity of arginase also results in the net 
synthesis of citrulline and release into the portal vein (Cynober et al, 2002). In contrast, 
appreciable ASS and ASL enzyme activities in the kidney in conjunction with very low 
renal arginase activity facilitate net arginine synthesis and release in to the peripheral 
circulation (Brosnan et al, 2003;  
Dhanakoti et al, 1990). Therefore, small intestinally-derived citrulline is the major 
precursor for renal de novo arginine synthesis; thus, the small intestinal–renal axis is 
considered as the major pathway for arginine de novo synthesis in adult humans. Using 
an in vivo amino acid tracer technique, Ligthart-Meliset al (2007; 2008) reported that 
arginine was synthesised from glutamate and glutamine in adult humans. However, those 
results were obtained using nitrogen-labelled tracers, which have been criticized because 
the movement of the tracer could potentially reflect transamination. Recently, a study by 
Tomlinson et al (2011b) used multiple carbon labelled tracers (arginine and proline) to 
determine whether dietary proline is a precursor for de novo arginine synthesis in adult 
humans. They demonstrated that 40% of newly synthesised arginine was derived from 
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dietary proline. Thus, proline is now considered an important dietary precursor for 
arginine synthesis in the adult human. A subsequent study by the same research group 
also clearly identified glutamine as a precursor for arginine, by using multiple glutamine 
tracers (13C and 15N). Based on the 13C tracer enrichments and flux, 50% of newly 
synthesised arginine was derived from glutamine (Tomlinson et al, 2011c).   
b. Arginine de novo synthesis in neonatal piglets 
Arginine concentration in sow milk is relatively low (4.4% of total amino acids at 
d 21 of lactation) compared to the concentration of some other indispensable and 
conditionally indispensable amino acids such as proline (11.7%), leucine (8.9%), lysine 
(7.9%) or glutamate and glutamine (20.8%) (Davis et al, 1994). Mature sow milk 
provides approximately 0.47 g/kg/d of arginine to the suckling neonatal piglet (Moughan 
et al, 1992). According to the NRC recommendations (1998), the dietary  
requirement for arginine for a healthy neonatal piglet is 0.38 g/kg/d; as such, it is met by 
the arginine concentration in sow milk. However, Brunton et al (2003) measured protein 
synthesis rates as a functional determinant of the adequacy of arginine intake in TPN-fed 
piglets; the IV intake necessary to maximize muscle protein synthesis was 1.2 g Arg/kg/d. 
Although sow milk is a relatively poor source of arginine, it contains abundant amounts 
of arginine precursors. Thus, sow-reared, neonatal piglets must synthesize at least some 
of their daily requirement of arginine to maximize growth. 
De novo arginine synthesis in neonates does not follow the intestinal-renal axis as 
has been described in adults. A series of studies in neonatal piglets have clearly shown 
that arginine synthesis occurs in the small intestine (Brunton et al, 1999; Bertolo et al, 
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2003; Wilkinson et al, 2004). Brunton et al (1999) were the first to demonstrate in 
neonatal piglets that feeding an arginine-free diet intravenously resulted in the rapid onset 
of severe hyperammonemia, despite the presence of proline in the diet. The same diet 
delivered intragastrically resulted in only moderate hyperammonemia after eight hours of 
feeding, indicating that de novo arginine synthesis occurred from dietary proline only 
when delivered into the gut. Bertolo et al (2003) used isotope kinetic analyses to isolate 
the metabolic roles of small intestine in the inter-conversions of arginine, proline and 
ornithine in neonatal piglets. This study isolated intestinal metabolism from hepatic and 
peripheral metabolism by infusing isotopes into the portal vein. They observed an 
absence of proline to ornithine conversion and very low ornithine tracer conversion into 
arginine during intraportal compared to intragastric tracer infusions. Furthermore, there 
was no difference in arginine to ornithine or ornithine to proline conversion between the 
two routes of  
feeding. Only 10% of proline requirement is synthesised in the small intestine while 50% 
of arginine requirement is synthesised in the gut (Bertolo et al, 2003). Accordingly, near 
absence of small intestinal proline de novo synthesis facilitated a net positive release of 
arginine into the portal blood. Bertolo et al (2003) were the first to use multiple tracers to 
estimate the arginine de novo synthesis in the small intestine. Wilkinson et al (2004) also 
found 42–63% of whole body arginine synthesis occurred during the first pass intestinal 
metabolism in neonatal piglets. Later, Urschel et al (2005) demonstrated that the hepatic 
contribution to net arginine synthesis is negligible. Indeed, they found that net arginine de 
novo synthesis is dominated by the small intestinal mucosa of neonatal piglets by 
29 
 
isolating the first pass hepatic metabolism through the infusion of intraportal and 
intravenous tracers. Based on the enzyme activities (in vitro) measured in mucosal tissues 
in humans and piglets (Kohler et al, 2008; Wu, 1998), and in vivo multitracer studies 
using various routes of administration in neonatal piglets (Bertolo et al, 2003; Wilkinson 
et al, 2004), it is clear that arginine de novo synthesis occurs predominantly in the small 
intestinal enterocytes in neonates.  
c. Arginine as a semi-indispensable amino acid for sow-reared neonatal piglets 
In contrast to healthy adults, healthy neonatal piglets have been shown to require 
at least part of their whole body arginine requirement from diet. Apparently, the capacity 
for de novo synthesis is not sufficient to meet the whole body requirement during rapid 
growth and development (Wilkinson et al, 2004; Kim & Wu, 2004). A recent study by 
Kim & Wu (2004) demonstrated that even under normal feeding circumstances, dietary 
arginine intake from sow milk might be inadequate. In  
this study, a sow-milk replacer was used to feed piglets. The formulas contained arginine 
at either the sow milk level, or supplemented with arginine at 0.2% and 0.4%. The piglets 
fed arginine at the sow-milk level had significantly lower plasma arginine, citrulline and 
ornithine concentrations by days 14 and 21 of age; this was accompanied by significantly 
higher plasma ammonia (Kim & Wu, 2004). Arginine supplementation enhanced daily 
weight gain by 28 and 66% in the two groups, compared to control piglets who received 
arginine at the sow milk level. The authors suggested that even normal, healthy neonatal 
piglets cannot synthesize adequate amounts of arginine to meet the requirement for rapid 
growth during early life. However, it is important to note that colostrum and sow milk are 
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also important sources of polyamines and other growth factors (Kelly et al, 1991; Motyl 
et al, 1995; Cheng et al, 2006) as well as providing exogenous creatine (Brosnan et al, 
2009). Thus, a formula diet containing arginine at the concentration found in sow milk 
may not produce a rate of growth that is truly reflective of the sow-reared piglet. 
d. Precursors for arginine de novo synthesis 
Sow milk contains abundant glutamate and glutamine, which were once thought to 
be potential precursors for arginine synthesis. However, in vivo and in vitro evidence 
suggests that glutamate cannot act as a precursor for arginine due to negligible activity of 
P5C synthase in the neonatal intestine (Wu 1998). P5C synthase catalyzes the conversion 
of glutamate to P5C, which can then be converted into ornithine via OAT, or proline via 
P5C reductase. Bertolo et al (2003) demonstrated the localisation of the OAT to the small 
intestinal mucosa of the neonatal piglet by measuring the conversion of labelled ornithine 
to proline and glutamate when infused  
intravenously versus intragastrically. However, they observed no differences in proline to 
glutamate or in ornithine to glutamate conversions between intraportal and intragastric 
tracer infusions (Bertolo et al, 2003). This was likely due to low P5C dehydrogenase 
(P5CDH) activity (Wu, 1998), which converts P5C into glutamate (Figure 1). Low 
P5CDH activity would increase the availability of proline as a precursor for arginine de 
novo synthesis in the neonatal gut. Wilkinson et al (2004) also demonstrated the 
conversion of intragastrically-delivered proline tracers into arginine, demonstrating 
arginine synthesis from dietary proline. However, they did not detect the glutamate tracer 
in arginine, indicating that there was biologically insignificant conversion of glutamate 
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into arginine. These findings are in contrast to the data found in adults, where 50% of de 
novo arginine synthesis was derived from the carbons of glutamine (Tomlinson et al, 
2011c). Thus, it is clear that dietary proline, but not glutamate or glutamine, is the 
precursor for arginine de novo synthesis in neonatal piglets. 
e. Arginine de novo synthesis in human neonate 
Until recently, it was only speculation that human neonates would have the 
capacity for de novo arginine synthesis, based on the knowledge that mammalian milk 
(including human milk) has a low concentration of arginine relative to the requirements 
for growth.  Furthermore, proline is abundant in human milk (Davis et al, 1994). In 2008, 
Kohler et al, reported that the fetal and perinatal human intestine has the ability to 
synthesise arginine, based on the enzyme activities measured in small intestinal 
enterocytes. A recent landmark study by Tomlinson et al (2011a) employed a multi-tracer 
stable isotope design in human neonates, and demonstrated  
that the precursor for arginine synthesis was proline but not glutamine. In that study, the 
researchers measured products of the proline isotope tracer (arginine, ornithine) in the 
urine of infants during isotopic plateau. However, the arginine product of a glutamate 
tracer, and the glutamate tracer itself, were not detected in the urine of the enterally-fed 
premature infants, indicating neither glutamate nor glutamine were precursors for 
arginine synthesis. 
The combined evidence from two neonatal piglet studies (Bertolo et al, 2003; 
Wilkinson et al, 2004) and the one human study by Tomlinson et al (2011a) clearly 
demonstrate that enterally-derived proline, but not glutamine or glutamate, is a major 
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dietary source for the de novo arginine synthesis in the small intestinal mucosa of 
neonates. 
1.4.2.2 Arginine and NO synthesis  
Arginine is the precursor for NO synthesis. The fraction of whole body arginine 
flux associated with NO synthesis (1.2%) in healthy adult humans is small (Castillo et al, 
1996). However, the plasma arginine compartment serves as a major precursor pool 
(54%) for whole body daily NO synthesis (Castillo et al, 1996). In healthy adults, the 
first-pass splanchnic use of dietary arginine is about 38% (Castillo et al, 1993a). 
However, the dietary arginine metabolized to NO during first pass splanchnic metabolism 
represents 16% of the whole-body nitrate production (Castilloet al, 1993b). Furthermore, 
in the healthy adult human, dietary arginine intake did not have an effect on NO 
synthesis, as both fed and fasted situations in adults resulted in approximately 1.2% of 
arginine turnover used for NO synthesis (Castillo et al, 1996). In contrast, dietary L-
arginine supplementation stimulated endothelial NO  
synthesis in adult rats (Kohli et al, 2004). Currently, there are no such data available for 
healthy human neonates. In sick neonates recovering from persistent pulmonary 
hypertension (PPHN), NO synthesis accounted for less than 0.5% of plasma arginine flux, 
which was less than the proportion of arginine converted into NO in healthy adults. In the 
same study of infants with PPHN, Castillo et al (1995) reported that the rate of plasma 
arginine conversion to NO synthesis was higher (45.6 µmol/d) when dietary arginine 
intake was 36 µmol/kg/h compared to the rate of NO synthesis (10.3 µmol/d) with a 
dietary arginine intake of 16 µmol/kg/h arginine. Urschel et al (2007) studied the 
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proportion of NO synthesis from dietary arginine in healthy neonatal piglets. In contrast 
to 0.5% of plasma arginine flux converted into NO in sick human neonates, Urschel et al 
(2007) demonstrated that NO synthesis accounted for 13% of whole body arginine flux in 
enterally fed neonatal piglets irrespective of the amount of arginine in the diet. In the 
Urschel study, the isotope tracers were infused into a gastric catheter, and as such 
included small intestinal NO synthesis, as opposed to Castillo’s study which used IV 
infusion. The difference between the two studies in the amount of arginine flux directed 
to NO synthesis is quite large, which may be due to the route of infusion, or the model 
used. Urschel et al (2007) fed either generous arginine (1.8 g Arg/kg/d) or a deficient diet 
(0.2 g Arg/kg/d) intragastrically to piglets, and found significantly higher whole body 
arginine conversion into NO with the higher intake. Accordingly, piglets fed the generous 
arginine diet had significantly higher NO synthesis compared to piglets fed the deficient 
arginine diet, but the proportion of whole body arginine converted into NO was not 
different. Thus, greater arginine intake led to greater NO production in both sick human 
neonates and neonatal piglets; however arginine deficient piglets could not up-regulate 
the NO synthesis.  
1.4.3 Arginine metabolism in pathological situations 
a. Arginine de novo synthesis in pathological situation: human neonate 
TPN feeding reduces plasma arginine in human neonates: Arginine is 
considered to be a conditionally indispensable amino acid for human neonates. It is 
unlikely, based on current evidence, that the healthy neonate can synthesise adequate 
arginine in the small intestinal mucosa from abundantly available precursors, suggesting 
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that arginine is semi-indispensable. Early in the history of TPN use for neonates, it was 
clear that there was a requirement for arginine in TPN solutions. Hypoargininemia in 
parallel with hyperammonemia was observed in three infants receiving total parenteral 
nutrition with a synthetic amino acid mixture (Heird et al, 1972). Interestingly, the 
hypoargininemia and accompanying hyperammonemia resolved with the administration 
of arginine intravenously, clearly demonstrating the inadequacy of arginine in neonatal 
TPN. However, the absolute requirement for arginine was not known; nor was it known 
that bypassing small intestinal metabolism would impair de novo synthesis of arginine. 
Later studies by Batshaw et al (1984) reported that premature neonates had elevated 
plasma ammonia and significantly lower plasma arginine and ornithine concentrations 
within the first two months of their life, compared to normal birth weight neonates. 
Again, elevated plasma ammonia was corrected by the provision of additional arginine in 
TPN. These findings suggest that the concentration of arginine in the intravenous diets 
used for premature human neonates was not sufficient to maintain ammonia 
detoxification, even with full TPN feeding.  
Prolonged TPN feeding, low plasma arginine and development of NEC: 
Prolonged TPN-feeding of human neonates places them at high risk of developing a 
clinical complication known as necrotizing enterocolitis (NEC). NEC is an aggressive, 
anaerobic infection that develops rapidly in the gastrointestinal tract of premature 
neonates during TPN feeding. This is the most common gastrointestinal emergency in 
premature infants, occurring in approximately 10% of all premature babies in North 
America (Di Lorenzo et al, 1995). Despite the fact that NEC has been a longstanding 
35 
 
medical issue in premature infants in the hospital setting, the pathophysiology of this 
infectious process is not well understood. Plasma amino acid analysis in premature 
neonates suffering from NEC showed that for most of the NEC cases, plasma arginine 
and glutamine concentrations were low at diagnosis (Di Lorenzo et al, 1995; Zamora et 
al, 1997). It is not yet clear whether NEC in the premature neonates interferes with 
arginine synthesis, or whether inadequate arginine availability to the small intestine 
contributes to the development of NEC. Becker et al (2000) followed premature infants 
from birth to identify factors that might contribute to the development of NEC. They 
reported significantly lower plasma arginine and glutamine concentrations at day 7 of life 
in infants who later developed NEC, compared to those who did not develop the disease 
(controls). The majority of NEC infants had parenteral amino acid intake that was double 
the intake of control infants. The infants who developed NEC were experiencing greater 
feeding intolerance at 7 days of age. Furthermore, irrespective of the higher arginine 
intake from TPN in the NEC group, plasma concentrations of arginine, glutamine and 
essential amino acids were still significantly lower even at 14 days of life. Accordingly, it 
is likely that lower plasma arginine concentrations in  
premature neonates may pre-dispose them to the development of NEC. This concept is 
further supported by the work done by Amin et al (2002). In that study, premature infants 
received either TPN supplemented with additional arginine, or at a standard arginine 
(control) concentration. Only 6.7% of premature infants on the higher arginine intake 
(398 mg/kg/day) developed NEC by day 20 of life. In comparison, 16.9 % of the infants 
on the lower arginine intake (181 mg/kg/day) developed NEC by day 10 of life. Plasma 
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arginine concentrations were also significantly higher in arginine-supplemented infants 
compared to the control group. This clearly indicates that TPN feeding with a standard 
commercial formulation results in sub-optimal arginine status in premature infants, 
predisposing them to NEC.  
b. Arginine metabolism and TPN feeding in neonatal piglets 
According to the NRC (1998), the dietary requirement of arginine for healthy 
neonatal piglets is 0.38 g/kg/d. However, hypoargininemia and hyperammonemia 
occurred during a TPN feeding trial in piglets provided arginine at the NRC requirement 
(Brunton et al, 1999). Even with slightly more than double the amount of arginine in the 
NRC recommendation, low plasma arginine and high ammonia concentrations were 
observed. This amount of arginine (1.0 g arginine/kg/d) is mid-range for the concentration 
delivered by the various commercial pediatric products. In the neonatal piglet, it is 
apparent that the concentration is not adequate to meet the metabolic demands for 
arginine during TPN feeding. Brunton et al (2003) demonstrated that 1.0 g/kg/d of 
arginine in TPN did not maximise muscle protein synthesis in TPN-fed neonatal piglets, 
which implies that although ureagenesis might be maintained, the demand for arginine for 
creatine biosynthesis, NO synthesis and growth may not be fulfilled. In the same study, 
plasma arginine concentration increased with increasing dietary arginine, and reached a 
plateau at a concentration similar to sow-fed reference piglets only when the piglets 
received greater than 1.2 g/kg/d of arginine. The plasma ammonia concentration was low 
and stable at this arginine intake while the muscle protein synthesis was maximised. 
Therefore, they suggested that metabolic arginine requirement for TPN-fed, neonatal 
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piglets must be 1.2 g/kg/d or higher. Arginine de novo synthesis becomes compromised 
during TPN feeding, and as such, the whole body arginine requirement must be met by 
the dietary (IV) intake. In infant studies that provided arginine in TPN at concentrations 
similar to human milk, hypoargininemia and hyperammonemia were reported among 
premature neonates (Batshaw et al, 1984). Therefore, de novo arginine synthesis in the 
neonatal intestine seems to be impaired in both humans and piglets during TPN feeding, 
as both experience hypoargininemia and hyperammonemia during exclusive IV feeding 
(Brunton et al, 1999; Batshaw et al, 1984).  
1.5 Blood flow in the small intestine 
1.5.1 General information on blood flow to the gut in humans 
The celiac artery, the cranial or superior mesenteric artery and the caudal or 
inferior mesenteric artery are three direct branches of the aorta that supply blood to the GI 
tract. The celiac artery supplies blood to the stomach, liver, and spleen, while the superior 
mesenteric artery, the largest single branch of the abdominal aorta, supplies the entire 
small intestine, proximal portions of the colon, and the pancreas. The inferior mesenteric 
artery delivers blood to the distal colon. In the small intestine, the duodenum is supplied 
by the duodenal branch of the superior mesenteric artery while  
the jejunum is supplied by jejunal branches of the superior mesenteric artery. The ileum 
and the distal end of the intestine are supplied by the ileal, right colic, ileocolic, and 
appendiceal branches of the superior mesenteric artery. The blood flow to the intestinal 
tissues is then distributed into the various layers of the small intestine known as localised 
blood flow. Total blood flow through the aortic branches which supply the small intestine 
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is increased when food is ingested. This increase in blood flow is transferred to the 
mucosal layer of which 60% is directed towards the villi while 40% reaches crypts (Chou 
et al, 1976). 
When the absorption of nutrients from a meal is complete, blood flow to the 
intestine returns to the food-deprived level. During digestion, blood flow increases and 
reaches a peak (15 – 20 % above the control) and stays elevated for 2 to 3 hours before 
returning to the unfed state (Chou et al, 1976).The portal vein collects nutrient-rich blood 
from intestinal tissues and supplies the liver before the nutrients are delivered to the post-
hepatic systemic circulation. In general, blood flow to tissues is auto-regulated by 
metabolic factors such as decreased PO2, pH, or osmolarity and increased PCO2 or 
adenosine. These mechanisms serve to maintain blood flow to meet the intestinal tissue 
requirements for oxygen and nutrients and to facilitate nutrient delivery and waste 
removal, thus preserving the function and the integrity of the intestine during digestion 
and absorption processes (Sparks, 1980; Matheson et al, 2000). The pig as a model has 
been widely used in experimental studies of human cardiovascular diseases as pig is 
similar to human in cardiovascular anatomy and physiology (Pond et al, 1978a). The 
figure 2.0 illustrates the blood circulation of the pig.  
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Figure 1.2: Blood circulation of the pig      
 Copyright © www.ThePigSite.com - Reproduced with Permission 
 
 
 
 
 
40 
 
1.5.2 Factors affecting blood flow 
There are differences between adults and neonates in blood flow to 
gastrointestinal tissues in response to macronutrient intake. In the neonatal piglet, the 
small intestine demonstrated increased blood flow to all the layers of the proximal half of 
the small intestine with gastric infusion of a lower concentration of glucose than was 
required in the adult animals (Dudgeon et al, 1981; Bohlen, 1980). The response by the 
healthy, neonatal small intestine indicated an exaggerated response to luminal nutrients 
compared to the adult gut. An increase in blood flow to the small intestine in response to 
a high fat diet has also been well established; however, the findings related to proteins 
have been less clear. One research study reported an increase in blood flow to the small 
intestine with a high protein diet (Siregar & Chou, 1982) while other studies reported 
little or no response to amino acids or dipeptides (Chou et al, 1978; Kvietys et al, 1980). 
The impact of the ingestion of free amino acids on small intestinal blood flow had not 
been investigated, to our knowledge, when we were planning the research described in 
this thesis. 
1.5.3 Arginine & NOS isoforms 
As arginine is the precursor for NO synthesis, inadequate arginine availability to 
vascular endothelial cells may negatively affect blood flow. The specific function of NO 
depends on which isoform of the NO synthase enzyme is responsible for its synthesis. 
Nitric oxide synthase (NOS) has three isoforms; the two constitutive isoforms are 
endothelial NOS (eNOS) and neuronal NOS (nNOS), and the one inducible form is 
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iNOS. The constitutive forms are expressed at low levels in a variety of tissues and cells 
while the inducible form does not express in significant levels  
under normal physiological situations (Garvey et al, 1997; Ford et al, 1997). An excessive 
level of NO production associated with iNOS expression is considered detrimental 
because its expression is associated with inflammation and ischemic injury (Alican & 
Kubes, 1996; Di Lorenzo & Krantis, 2001; Gookin et al, 2002). eNOS, which is 
concentrated in the endothelial cells (closer to the vascular smooth muscle cells), is 
responsible for the vascular diameter and thus, hemodynamic properties of the vessel. NO 
synthesised from eNOS is the most potent vasodilator in the newborn intestine (Nankervis 
et al, 2001). The NOS isoforms are unique in their function and their location. The NO 
produced by iNOS does not substitute for NO synthesised from eNOS. Thus, iNOS-
derived NO does not participate in vascular regulation, nor does eNOS-derived NO 
participate in the inflammatory response (Nowicki et al, 2007). 
1.6 TPN feeding & small intestinal atrophy 
Small intestinal atrophy has been characterised by reduced small intestinal 
mucosal weight, villous height, mucosal protein mass, protein synthesis, crypt cell 
proliferation and polyamine synthesis secondary to reduced ornithine decarboxylase 
(ODC) activity and small intestinal goblet cell expansion. Intestinal atrophy, induced by 
TPN feeding, has been shown to occur in neonatal animals, and to a lesser extent in 
human neonates (Rossi et al, 1993; Dudley et al, 1998; Bertolo et al, 1999a & b; Conour 
et al, 2002; Niinikoski et al, 2004). Indeed, intestinal atrophy has been well documented 
in TPN-fed neonatal piglet models (Goldstein et al, 1985; Bengmark & Gianotti, 1996; 
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Bertolo et al, 1999a & b; Conour et al, 2002; Kansagra et al, 2003; Burrin et al, 2003; 
Niinikoski et al, 2004). During a 3 week feeding study, 6 week old  
intravenously-fed piglets had significantly lower total small intestinal weight compared to 
piglets that were fed with the same formula into a gastric catheter (Goldstein et al, 1985). 
Furthermore, small intestinal length, villous height, crypt depth and epithelial cell number 
were significantly lower compared to values obtained for piglets that were fed an oral 
chow diet for 3 weeks. Dudley et al (1998) observed a significant reduction of fractional, 
absolute and total mucosal protein synthesis after 6 days of parenteral feeding in 3 d old 
neonatal piglets, compared to enterally-fed piglets provided the same formula. Bertolo et 
al (1999a & b) induced extensive gut atrophy in neonatal piglets within 7 days of TPN-
feeding. They reported significantly lower small intestinal weight compared to controls. 
In addition, the mucosal wet weight was significantly lower in all sections of the small 
intestine, and the villous height was shorter in the duodenum. Total body nitrogen content 
and nitrogen retention were also significantly low in intravenously-fed compared to 
intragastrically-fed neonatal piglets. The small intestinal mucosal nitrogen content was 
also significantly lower in the intravenously fed animals, but the nitrogen content in the 
liver and kidney were not significantly different between treatment groups. This suggests 
that the body as a whole is affected by gut atrophy. It is also clear that the absence of 
luminal nutrients contributes to small intestinal atrophy, despite the provision of adequate 
parenteral nutrients. 
Conour et al (2002) also used the neonatal piglet model to demonstrate TPN-
induced gut atrophy. They killed a group of animals at 1 day old (study day 0) to get 
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base-line measurements, while two other groups were fed with either TPN or TEN (Total 
Enteral Nutrition) for 3 or 7 days. They reported significantly lower jejunal  
villous heights in piglets that were fed TPN for 3 days or 7 days compared to piglets that 
received TEN.  The jejunal crypt depth was also significantly lower in 7 d TPN-fed 
neonatal piglets compared to piglets fed TEN for 7 days. Both of these histomorphometric 
characteristics were significantly lower in the TPN group compared to the values obtained 
from reference  piglets  killed at 1 d old (base-line).  
In neonatal piglets, the enterocyte life span is 3-5 d, depending on the location along the 
small intestine (Fan et al, 2001). As described above, Conour et al (2002) found that after 
only 3 days of TPN feeding, newborn term piglets demonstrated small intestinal 
morphologies that were inferior to measurements obtained from animals killed at study 
day 0. However, the differences between 3 and 7 days of TPN feeding were negligible; 
thus, it likely takes only 3 days of TPN to induce intestinal atrophy. Niinikoski et al, 
(2004) investigated TPN-induced gut atrophy using neonatal piglets that were studied at 
18-22 days old. All piglets were enterally fed and then randomized to TPN feeding or 
were continued on the enteral diet. The researchers observed reduced jejunal mass and 
jejunal villous height after only 24 h of TPN feeding, when compared to enterally-fed 
piglets. Mucosal fractional protein synthesis was also significantly reduced by 24 h of 
TPN. Jejunal crypt cell proliferation, rates of villus and crypt epithelial cell apoptosis in 
the jejunum and DNA mass were not different at 24 h of TPN feeding compared to 
enteral feeding. However, they were significantly reduced by 48 h of TPN feeding. Thus, 
the magnitude of the reduction of mucosal morphometric characteristics was profound 
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even by 48 h of TPN.  The data are clear from the studies by Conour et al (2002) and 
Niinkoski et al (2004) that the process of TPN-induced intestinal atrophy is well 
established within 2-3 d of TPN feeding in neonatal piglets. 
1.7 TPN feeding and reduced blood flow: piglet studies 
 An important question related to TPN-induced intestinal atrophy is how atrophy 
affects arginine metabolism and de novo arginine synthesis. It is well established that 
arginine becomes an indispensable amino acid in neonatal piglets during TPN feeding, as 
the de novo synthesis is compromised without first pass SI metabolism. Therefore, if 
there is inadequate arginine available during TPN feeding for NO synthesis in the blood 
vessels, the consequence may be reduced blood flow to the small intestine. Niinikoski et 
al, (2004) investigated portal and superior mesenteric arterial (SMA) blood flow during 
the transition from a food-deprived state to enteral feeding and then to TPN feeding in 18-
22 d old neonatal piglets. SMA blood flow was measured during food deprivation, and 
then during 8 h of duodenal feeding followed by 20 h of TPN infusion. With the initiation 
of enteral feeding, the SMA flow increased by 30% compared to the food-deprived 
baseline. Four hours after the transition to TPN feeding, the SMA flow then significantly 
decreased compared with the mean 8-h enteral infusion rate. The flow appeared to 
stabilize at a rate that was 40% lower than the enteral blood flow rate, which was 10% 
lower than the food deprived rate. The portal blood flow was also expressed as the change 
from the mean blood flow during the period of food deprivation. Portal flow increased 
significantly after the start of duodenal feeding and remained 30% above the baseline 
level in piglets administered the continuous duodenal infusion. In TPN-fed piglets, portal 
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flow decreased to the baseline values after ~7 h of TPN. These data demonstrate clearly 
that both portal and SMA blood flow changed within a few hours of the initiation of  
enteral feeding (after food deprivation) and dramatically reduced after the transition from 
enteral to TPN feeding. Based on these results, it is evident that TPN acutely reduces 
blood flow to the intestine relative to enteral feeding. It is also apparent from the above 
study that the significant declines in intestinal blood flow in response to TPN feeding 
occurred quickly (less than 8 h), and likely preceded the morphological changes observed 
by others. However, this information is not adequate to elucidate whether the reduction of 
SMA blood flow is responsible for the gut atrophy, or whether rapid gut atrophy occurs 
independent of blood flow in TPN feeding (Niinikoski et al, 2004). 
Reduced eNOS expression, which is the isoform responsible for the NO synthesis 
in the vascular endothelial cells, may be a reason for the reduced blood flow during 
prolonged TPN feeding. Reber et al (2002) studied 1, 3 and 10 d old fed and non-fed 
piglets in order to investigate the effect of enteral feeding on eNOS mRNA level and 
eNOS protein expression in mesenteric artery. They observed significantly higher eNOS 
protein expression in 1 d old fed piglets compared to 1 d old non-fed piglets. In piglets 
that were fed, the eNOS expression was significantly higher in the 10 d compared to 1 d 
old piglets. They also observed significantly higher blood flow in the mesenteric artery of 
1 d old fed piglets compared to 1 d old non-fed piglets. Similarly, blood flow was 
significantly higher in 3 d old fed piglets than in 1d old fed piglets. This suggests a 
connection between increased eNOS expression in small intestinal mesenteric artery and 
blood flow to the small intestine during postnatal enteral feeding. In contrast, Niinikoski 
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et al (2004) investigated NOS activity in intestinal tissues taken from 3 week old neonatal 
piglets after TPN feeding. Despite a  
reduced SMA blood flow, they measured no change in cNOS activity (eNOS and nNOS) 
or eNOS abundance. However, Niinikoski did not measure the eNOS activity or 
abundance in the mesenteric artery. Therefore, the data from the study by Niinikoski et al 
(2004) suggests that reduced SMA blood flow during TPN feeding may not be related to 
eNOS enzyme activity and/or eNOS protein abundance in small intestinal tissues. Instead, 
the feeding-induced change in SMA blood flow may be a systemic effect rather than a 
local effect.  
1.8 Partial Enteral Nutrition and SI atrophy in neonatal piglet 
It is evident that enterally derived nutrients are more readily available for small 
intestinal metabolism compared to systemic extraction, including most of the amino 
acids. However, full enteral feeding is not always possible in sick and/or premature 
neonates. The practice of giving small amounts of diet enterally has been adopted 
clinically, which is referred to as minimal enteral nutrition. However, the minimum 
amount or the nutrient composition that is needed to sustain small intestinal growth and 
function in neonates is not clear. Burrin et al (2000) quantified the total amount of the 
nutrient intake that was required enterally for the stimulation of small intestinal growth 
and normalisation of gut function. In that study, 7 day old neonatal piglets received the 
same total nutrient intake, of which 0, 10, 20, 40, 60, 80 or 100% was given enterally; the 
balance of intake was given intravenously. The animals were fed continuously for 7 days. 
Compared to TPN-fed controls, the piglets that received 40% of total nutrient intake 
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enterally had greater small intestinal mucosal mass, protein mass and villus height. 
However, 60% of the diet given enterally was required to sustain normal mucosal cell 
proliferation, small intestinal crypt depth and villi height,  
and ODC (ornithine decarboxylase) activity. Plasma concentrations of glucagon-like 
peptide 2 (GLP-2) and peptide YY (PYY), which are considered to be good candidates 
for intestinal growth regulators, were also significantly higher with 60% of the diet fed 
enterally (Burrin et al, 2000). However, we do not know which dietary components, 
delivered enterally, were responsible for eliciting the responses in small intestinal 
morphological outcomes. 
1.9 Rationale and Objectives 
Absence of enteral feeding is considered the underlying reason for small intestinal 
mucosal atrophy. Burrin et al (2000) demonstrated that at least 60% of the daily nutrient 
intake provided enterally was required to avoid compromising small intestinal 
metabolism induced by TPN feeding. Providing more than 60% of all the nutritional 
requirements orally or enterally may not be possible with sick neonates. The mechanisms 
by which luminal nutrients influence small intestinal mass are not fully understood, nor is 
it known whether single or multiple specific nutrients are more important for regulating 
small intestinal mucosal development. However, the luminal presence of specific nutritive 
factors such as amino acids may act as trophic factors to sustain intestinal growth and 
integrity during TPN feeding or when enteral re-feeding is initiated.   
Arginine is a good candidate to investigate potential trophic effects as it 
participates in many important metabolic pathways including NO synthesis, ureagenesis, 
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polyamine synthesis and protein synthesis. Numerous studies have shown that TPN 
feeding attenuates SMA blood flow in parallel with intestinal atrophy. Arginine is the 
precursor for NO synthesis, which is a key vasodilator in vascular  
endothelial cells. Therefore, limited arginine availability to the endothelial cells of gut-
atrophied neonatal piglets may lower SMA blood flow. Arginine also represents 6.7% of 
total body protein in neonatal piglets. Thus limited arginine availability in neonatal 
piglets may adversely affect the fractional protein synthesis in tissues which are highly 
proliferative such as small intestinal mucosa. For these reasons, arginine may have a 
particularly important role in preventing or ameliorating intestinal atrophy.  
Arginine is synthesised in the small intestinal enterocytes in healthy neonates. 
TPN-induced gut atrophy is well established in the neonatal piglet model. Arginine 
becomes an essential amino acid in TPN-fed neonates as the atrophied gut has reduced 
metabolic activity and is deprived of enteral proline as a dietary precursor. Thus, the 
entire requirement for arginine needs to be provided by endogenous synthesis during TPN 
feeding. Therefore, we investigated whether a high concentration of dietary arginine, 
delivered as the sole nutrient into the gut, could facilitate recovery from TPN-induced 
intestinal atrophy in neonatal piglets. 
We hypothesised that in neonatal piglets, enteral delivery of high compared to low 
arginine would act as a trophic factor, resulting in greater small intestinal fractional 
protein synthesis, greater crypt cell proliferation and greater SMA blood flow compared 
to TPN-fed piglets. We also hypothesised that enteral delivery of low arginine to gut-
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atrophied piglets would produce attenuated responses compared to enteral delivery of 
high arginine.  
 
 
 
Objectives: 
In piglets that were provided high or low concentrations of arginine either enterally or 
parenterally, our objectives were to: 
1. assess the effects of dietary arginine concentration and route of delivery on 
small intestinal morphology, small intestinal mucosal protein synthesis rate 
and SMA blood flow. 
2. assess the effect of dietary arginine concentration and route of delivery on 
liver, skeletal muscle and kidney protein synthesis rates 
3. assess the effect of arginine concentration and route of delivery on plasma 
urea, ammonia, and amino acid concentrations, as well as tissue free amino 
acid concentrations. 
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2.0 Methodology 
2.1 Animals   
The Institutional Animal Care Committee (Memorial University of 
Newfoundland) approved all the procedures used in this study. Yucatan miniature piglets, 
aged 14 to 17 d old, were obtained from Animal Care Services, Memorial University of 
Newfoundland. The study was designed to obtain animals as litter mates, with four 
animals used from each of six litters. However, blocking by litter was incomplete because 
of unplanned mortalities during the study (described in detail in section 3.0). 
In this study, we calculated that we would need a sample size of n = 6 per group 
(with α = 0.05 and β = 0.8).  This sample size allowed for detection of a 20% difference 
in the rate of mucosal protein synthesis and would detect a 30% increase mucosal weight 
per cm of mucosal length.  
2.1.2 Surgical procedure 
Piglets were transported from the Vivarium (the Animal Care Services breeding 
and housing facility) to the Biotechnology building. Upon arrival, piglets were pre-
anesthetised with an intramuscular injection of ketamine hydrochloride (22 mg/kg, 
Bimeda Canada, Cambridge, Ontario) and acepromizine (0.5 mg/kg, Vetoquinol, Canada, 
Inc, Quebec) as a single dose. Atropine (Rafter &Products, Canada) (0.05 mg/kg) was 
also given as sub-cutaneous injection to reduce air-way secretions during surgery. The 
animals were intubated to assist the piglet in maintaining respiration during surgery. The 
anaesthesia was maintained with 1.5 – 2 % isoflurane (Abbott Laboratories Inc., Canada) 
delivered with oxygen at 1.5 L/min  
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via the endotracheal tube. The heart rate and oxygen saturation were continuously 
monitored using a pulse-oximeter. Body temperature was maintained via a homeothermic 
blanket system that automatically adjusted heat output in response to a rectal temperature 
probe. 
Eighteen of the 24 piglets were subjected to diet intervention, and as such, were 
designated as “experimental animals”. The experimental animals were implanted with a 
silastic catheter into the left jugular vein, which was advanced to the superior vena cava 
cranial to the heart. The jugular catheter was used for diet infusion. Another silastic 
catheter was implanted into the left femoral vein and advanced to the inferior vena cava 
caudal to the heart. The femoral vein catheter was used for the blood sampling and drug 
infusion. A silastic gastric catheter was also implanted using the Stamm gastrostomy 
technique (Rombeau et al. 1984), but only into piglets that received an intra-gastric (IG) 
infusion of arginine (n = 12). To facilitate chronic blood flow measurements, a 4 to 6 mm 
ultrasonic perivascular blood flow probe (Transonic Systems Inc., USA) was implanted 
on the SMA. Once the SMA was isolated, and the ultrasonic probe was in place, the space 
between the vessel and the reflector bracket of the probe was filled with ultrasonic gel 
(Aquasonic, Parker Laboratories, Inc., USA) mixed with non-heparinized blood. The 
quality of the signal from the probe was tested before the site was closed. The lead wire 
of the ultrasonic probe was tunnelled under the skin, and exteriorized on the back to 
facilitate chronic blood flow measurements without removing the piglet from its cage. 
A group of piglets that remained with the sow for the duration of the study (sow-
fed, SF Reference) (n = 6) also underwent surgery for the implantation of only a  
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jugular venous catheter that was fitted with a subcutaneous port. This allowed for daily 
blood sampling with lower risk of infection or damage; immediately following recovery 
from surgery, these SF piglets were returned to the sow and remained with the litter until 
d 7 of study.  
2.1.3 Animal housing 
The experimental animals were fitted with jackets and were placed in individual 
metabolic cages. A swivel and tether system (Lomir Biomedical Inc., Canada) allowed 
the piglets to have free movement in the cages while maintaining continuous diet 
infusions. The cages were fitted with heat lamps and the room temperature was 
maintained at 25oC. A 12:12-h light-dark cycle was maintained. 
2.1.4 Post surgical care 
Immediately following surgery, piglets were given 0.5 mL of Borgal (40 mg 
trimethorprim and 200 mg sulfadoxine/mL) (Intervet Canada Ltd., Canada) and analgesic 
(0.03 mg/kg buprenorphine hydrochloride) (Temgesic, Reckitt Benckiser Healthcare, 
UK). The analgesic was given every 12 h for two days post-operatively. Subsequent 
doses were given if piglets showed signs of discomfort, such as limited movement. 
Antibiotics were also continued until study day 3. Again subsequent doses were given as 
needed if piglets exhibited signs of infections such as fever, lethargy, poor wound healing 
with pus, vomiting or altered breathing. The incision sites were covered with an 
antibacterial veterinary ointment each morning until they healed recovered. Immediately 
following surgery, all piglets received a continuous infusion of total parenteral nutrition 
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(TPN) that contained a moderate arginine concentration, providing 1.0 g/kg/d until the 
morning of day 4.  Parenteral nutrition (diets described  
below) was initiated at 50% of the maximal rate and increased to 75% on the morning 
following surgery, and was advanced to full TPN (13.5 mL/kg/h) by the evening of d 1.  
This allowed the piglets to adapt to the fluid load and to reduce the metabolic stress that 
accompanies intravenous feeding. 
2.2 Study protocol 
Small intestinal atrophy was induced by TPN feeding (“adaptation period”) until 
the morning of d 4 (Conour et al, 2002).Subsequently, the diets were changed such that 
12 piglets were randomized to receive a low dietary concentration of arginine via the 
gastric catheter (IG-L Arg) (0.6 g /kg/d), or a high concentration of arginine (IG-H Arg) 
(1.6 g /kg/d). These two groups were also provided with arginine-free TPN solution 
intravenously, to meet the remainder of their nutrient requirements. The third group 
continued on exclusive TPN with no intra-gastric infusion, but the TPN was modified to 
contain a high concentration of arginine (1.6 g/kg/d) (IV-H Arg). Thus the IG-H Arg and 
IV-H Arg received an identical concentration of arginine; only the route of delivery 
differed. The test diets were continued until the end of the study on d 7. The experimental 
protocol is described in Figure 2. 
The low dietary concentration of arginine (0.6 g Arg/kg/d) was selected based on 
a number of factors. A previous study of intragastrically-fed neonatal piglets 
demonstrated that 0.6 g Arg/kg/d was adequate to avoid hyperammonemia, but resulted in 
low plasma arginine concentrations (Brunton et al, 2003). Also, this intake level is 50% 
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greater than the NRC recommendation for young piglets of 0.4 g/kg/d, which we believe 
is inadequate. The high dietary concentration (1.6 g Arg/kg/d) was  
chosen based on data that suggested that the whole body dietary requirement for arginine 
is greater than 1.2 g Arg/kg/d in TPN-fed neonatal piglets (Brunton et al, 2003). 
Therefore, the amount selected for this study (1.6 g/kg/d) was likely in excess of 
requirements. A moderate amount of arginine (1.0 g/kg/d) was used during the adaptation 
TPN feeding period (days 0 to 4).  This concentration is equivalent to a commercially 
available amino acid product used in TPN solutions for human neonates (Vaminolact-
Fresenius Kabi, Germany), and is likely marginally deficient, according to previous 
findings (Brunton et al, 2003). 
The intragastric infusion of arginine was provided at 2 mL/kg/h continuously 
using a syringe pump. This provided 0.6g/kg/d and 1.6 g/kg/d of arginine alone into the 
gastric catheters.  
2.2.2 Preparation of diet 
a. TPN preparation 
All the diets were prepared in the laboratory.  The amino acid concentrations for each 
TPN diet are presented in Table 2.1.  The amino acids were sourced from either Sigma 
(St. Louis, MO, Canada) or from LV Lomas (Ajinomoto Company Inc, Japan, via LV 
Lomas, Brampton, Canada).Free L-arginine was used to make the diets. The amino acids 
were weighed on an analytical balance, and then mixed thoroughly as dry ingredients 
before adding to HPLC grade water in 4 L beakers on stir plates. The water was heated to 
55oC-65oC prior to the addition of small aliquots of the amino acid mixture to facilitate 
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dissolving.  The amino acids were mixed and dissolved under a blanket of nitrogen gas to 
protect amino acids from oxidation. All the diets were designed to provide 15 g amino 
acids/kg/d and 1.1 MJ metabolizable energy/kg/d with glucose and lipid each supplying 
50% of non-protein energy. All of the experimental diets were isonitrogenous, via the 
manipulation of serine. In general, the amino acid pattern was based on that of a 
commercial total parenteral nutrition solution (Vaminolact-Fresenius Kabi, Germany) 
with slight modifications. Once the amino acids were completely dissolved, D-glucose 
and minerals were added (Table 2.2). Finally, the solution was brought up to the final 
total volume by adding HPLC-grade water. The diets were sterilized via filtering through 
a 0.22 µm filter (AcroPakTM, Pall Life Sciences, USA) in a laminar flow hood. The 
filtered diet was infused directly into sterile intravenous bags (Baxter, Canada), and 
refrigerated until needed.   
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Figure 2.1: Experimental design 
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Table 2.1: Amino acid profiles (g/L)*of TPN diets 
 
 
 
 
Adaptation** IV-H Arg  IG-H Arg  IG-L Arg  
alanine 4.50 4.50 4.50 4.50 
arginine*** 3.68 5.88 0 0 
aspartate 3.36 3.36 3.36 3.36 
cysteine 0.80 0.80 0.80 0.80 
glutamate 5.81 5.81 5.81 5.81 
glycine 1.51 1.51 1.51 1.51 
histidine 1.71 1.71 1.71 1.71 
isoleucine 2.55 2.55 2.55 2.55 
leucine 5.76 5.76 5.76 5.76 
lysine-HCL 5.73 5.73 5.73 5.73 
methionine 1.07 1.07 1.07 1.07 
phenylalanine 3.03 3.03 3.03 3.03 
proline 4.58 4.58 4.58 4.58 
serine 5.33 0 0 8.90 
taurine 0.25 0.25 0.25 0.25 
tryptophan 1.17 1.17 1.17 1.17 
tyrosine 0.43 0.43 0.43 0.43 
valine 2.93 2.93 2.93 2.93 
threonine 2.24 2.24 2.24 2.24 
*The diets not including lipid, but containing amino acids, D-glucose, minerals, trace 
elements, vitamins and iron were infused at a rate of 272 mL/kg of body weight/day 
**Adaptation TPN fed to all experimental piglets until d 4, to induce intestinal atrophy 
***Arginine was not included in the IG-H Arg and IG-L Arg TPN diets, but was infused 
enterally.  The amount of arginine given enterally would be equivalent to 5.88 g/L (IG-H 
Arg) or 2.21 g/L (IG-L Arg) if included in the TPN solutions described in this table.   
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Table 2.2: Composition of the TPN diets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 g/L 
Amino acids 
D-Glucose 
Trihydrate K2HPO4 (g) 
Monobasic KH2PO4 (g) 
Potassium acetate (g) 
NaCl (g) 
MgSO4 (g) 
ZnSO4 (g) 
Calcium gluconate (g) 
55.3 
90.3 
1.57 
1.09 
1.47 
2.17 
0.78 
0.09 
6.41 
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b. TPN Admixture Components 
The salts listed in the Table 2.3 were dissolved in HPLC-grade water and then filtered 
through a 0.22 µm filter (Millipore Ireland ltd., Ireland) into sterile vacuum sealed bottle 
(Baxter, Canada) and stored at 4oC. Just prior to feeding the intravenous diets, each bag 
containing 750 mL of diet was injected with 3 mL of Multi-12/K1 pediatric multivitamin 
commercial solution designed for TPN feeding (Table 2.4) (Baxter, Canada), 1 mL of 
iron dextran that provides 3 mg of iron (ferric hydroxide) per kg of body weight 
(Vetoquinol Canada Inc., Canada), 3 mL of trace element mix (Table 2.3) and 145 mL of 
20% Intralipid (Fresenius Kabi, and Uppsala, Sweden). The vitamin mix provided all 
vitamins at more than 100% of the NRC (1998) requirement for neonatal piglets, and the 
trace element mix provided a minimum of 200% according to the NRC. 
c. Intragastric arginine infusions 
The intragastric infusion solution of arginine was prepared similar to the 
procedure for TPN diets, except only arginine was added to heated water so that the base 
arginine solution contained 12.5 g Arg/L and 33.34 g Arg /L for the IG-L Arg and IG-H 
Arg infusions, respectively. The infusates were filtered and stored in sterile intravenous 
bags (Baxter, Canada) at 4oC as described above.  
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Table 2.3:  Trace element mix 
  
 
 
 
 
 
 
 
 
BW – Body weight 
 
 
 
 
 
 
 
 
 
Element 
 
Minerals 
supplied as: 
 
Mineral  
Salt 
 (g/L) 
 
SingleElement  
Dose 
 (mg/kg of BW/d) 
Zinc 
Copper 
Manganese 
Chromium 
Selenium 
Iodide 
ZnSO4.7H2O 
CuSO4.5H2O 
MnSO4.H2O 
CrCl3.6H2O 
SeO2 
NaI 
40.69 
3.12 
1.86 
0.05 
0.06 
0.02 
10.07 
0.86 
0.66 
0.01 
0.05 
0.02 
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Table 2.4: Commercial multi-vitamin mix* designed for TPN feeding 
 
Vitamins Amount in 
5 mL of  
vitamin mix * 
Dose 
(per kg of BW/day) 
Ascorbic acid (mg) 
Vitamin A (IU) 
Vitamin D (IU) 
Thiamine (as hydrochloride) (mg) 
Riboflavin (as phosphate) (mg) 
Pyridoxine hydrochloride (mg) 
Niacinamide (mg) 
d-Panthenol (mg) 
Vitamin E (dl-alpha tocopheryl 
acetate) (IU) 
Vitamin K1 (mg) 
Biotin (µg) 
Folic Acid (µg) 
Vitamin B12 (cyanocobalamin) (µg) 
80 
2300 
400 
1.2 
1.4 
1 
17 
5 
 
7 
0.2 
20 
140 
1 
17.41 
500.48 
87.04 
0.26 
0.30 
0.22 
3.70 
1.1 
 
1.52 
0.04 
4.35 
30.46 
0.22 
 
*Multi-12/K1Pediatric Multivitamin Mix (Baxter, Canada); Vitamins are provided as two 
separate solutions, that are mixed just prior to use (final volume 5 mL).  3 mL of the 
prepared solution was added to each 750 mL diet bag, to deliver the vitamin doses 
described above. BW – Body weight 
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2.3 Daily care  
A daily care record was maintained for each animal during the study that included 
total weight of diet infused, daily piglet weight, drug records and general comments about 
the piglets’ wellbeing. 
2.3.1 Blood sampling, animal weighing and adjusting diet infusion rates 
The blood volume of a neonatal piglet is approximately 10% of body weight.  A 2 
week-old piglet weighs approximately 2.5 kg, therefore the total blood volume is ~250 
mL. A guideline for blood sampling without affecting the health of the piglet is 2% of the 
total blood volume (5 mL) every second day, as young pigs are capable of producing 
erythrocytes at a rate proportional to their increase in body weight if adequate iron is 
available (Talbot & Swenson, 1970). In this study, we sampled 2.5 mL of blood every 
morning prior to flushing the lines with heparinized saline. The plasma was separated and 
stored at -20oC until needed for analyses. Animals were weighed every morning and the 
diet infusion rate was adjusted to accommodate daily weight gain. The pump efficiency 
was also calculated daily and the rates of diet infusion were adjusted accordingly. 
2.3.2 Blood flow reading 
Blood flow rate was measured every 12 h beginning from d 3 and was recorded 
for a 15 min interval each time. The data were averaged for the period, and converted 
from a voltage measurement to mL/min using a conversion factor supplied by the 
manufacturer (Transonic Systems Inc., USA). A baseline blood flow was established as 
the mean blood flow of individual animals during the 36 h period prior  
to initiation of the test diets (ie the average of the blood flow measures on study d 3  
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morning and afternoon and study d 4 morning). Subsequently, blood flow after the 
initiation of the test diets was expressed as the percentage of the baseline blood flow. 
Therefore, the baseline blood flow represented blood flow while all the piglets were fed a 
moderate amount of arginine in TPN.   
2.4 Isotope infusion protocol and necropsy procedure 
On study d 7, a bolus IV dose of 5-bromodeoxyuridine (BrdU) (50 mg/kg body 
weight) (Sigma Aldrich, Oakville, Canada) was infused intravenously 4 h prior to the 
necropsy to facilitate the measurement of in vivo small intestinal crypt cell proliferation 
index(described below in section 2.5.2).  
A flooding dose of unlabelled phenylalanine (1.5 mmol/kg) (Sigma Aldrich, 
Oakville, Canada) was administered over 5 minutes, along with tritiated phenylalanine (1 
mCi of L-[4-3H] phenylalanine/kg body weight) (GE Biosciences/Amersham 
Biosciences, Oakville, Canada) via the jugular vein catheter. This was done 30 minutes 
before the necropsy to measure the tissue specific fractional protein synthesis rates 
(described in section 2.5.1.2). The intravenous TPN infusion was stopped during the 5 
minute infusion.  
Thirty minutes following the phenylalanine infusion, piglets were anaesthetized 
by mask (halothane/oxygen). The abdomen was opened and the entire gut weight and 
length were recorded. A 60 cm long section of the proximal jejunum was flushed with 
ice-cold saline, and the mucosa was scraped from the muscle layers using a glass 
microscope slide. The mucosa was weighed, and frozen in liquid nitrogen and stored at -
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70oC. Samples of liver, left kidney and skeletal muscle (gastrocnemius) were also frozen 
in liquid nitrogen, and the exact time the tissues  
entered the liquid nitrogen was recorded.  Tissues were stored at -70oC. A section of 
proximal jejunum was formalin-fixed for histological analyses. The positions of the SMA 
blood flow probe and all the catheters were verified at necropsy. The piglets were killed 
while still under anaesthesia via exsanguination after the removal of the liver. 
2.5 Analytical procedures 
2.5.1 Biochemical analysis of plasma, tissue amino acids and protein synthesis 
2.5.1.1 Plasma amino acid analysis 
a. Plasma preparation and derivatization for amino acid analysis via HPLC 
Plasma amino acids were analysed by reverse-phase high-performance, liquid 
chromatography (HPLC) using phenylisothiocyanate derivatives (PITC, Waters, Woburn 
MA) as per the method of Bidlingmeyer et al (1984).  HPLC is a technique that can be 
used to separate and then to identify and/or quantify individual amino acids. The eluent A 
used in the HPLC Waters Pico Tag method contains HPLC grade water and sodium 
acetate trihydrate (Fisher Scientific, Whitby, Canada) and acetonitrile (Fisher Scientific, 
Whitby, Canada) at pH ~6.55. The eluent B contains acetonitrile, HPLC water and 
MeOH. Both of the eluents were filtered using 0.45 µm Magna nylon filter paper 
(Thermos Scientific, Canada). Eluent A allows separation of hydrophilic amino acids 
while eluent B allows separation of hydrophobic amino acids. In detail, 20 µL of 2.5 
µmol/mL norleucine standard (Sigma Aldrich, Oakville, Canada) was added to 100 µL of 
plasma with 1 mL of 0.5% trifluoroacetic acid (TFA) (Sigma Aldrich, Oakville, Canada) 
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in methanol (MeOH) (Fisher Scientific, Whitby, Canada) and vortexed to precipitate 
proteins. The samples were centrifuged at 4200 g to separate the plasma proteins. The 
resulting supernatant was frozen in liquid nitrogen and dried on the freeze dryer (Thermo 
Savant, Canada) overnight. 50 µL of a solution of 20:20:60 of triethylamine (TEA) 
(Sigma Aldrich, Oakville, Canada): MeOH: water was added to each dried sample, 
followed by ~1 hour freeze drying. This step was to adjust the pH for the derivatization. 
Samples were then incubated with 20 µL of 10:10:70:10 solution of water: TEA: water: 
MeOH: PITC (Thermo Scientific, USA) for 35 minutes at room temperature. This 
derivatization step allows PITC to bind with free amino acids to form phenylthiocarbamyl 
amino acids. The phenylthiocarbamyl amino acids in solution are relatively stable in 
neutral pH. The labelling with PITC was stopped by freezing with liquid nitrogen and the 
samples were placed on a freeze dryer overnight. Prior to measuring on the HPLC, the 
samples were re-suspended in 200 µL of sample diluent (710 mg of Na2HPO4 (Sigma 
Aldrich, Oakville, Canada) in 1 L of HPLC water, titrated to pH 7.4 with 10% H3PO4 acid 
and diluted with acetonitrile so that the acetonitrile equals 5% by final volume). Samples 
were centrifuged and the supernatant was transferred to 0.25 mL Eppendorf tube. 
c. HPLC analysis of plasma samples 
The HPLC system is fitted with an auto-sampler such that up to 48 samples may be 
injected sequentially. A 40 µL aliquot of sample was injected into the HPLC column. The 
reverse phase C18 column temperature was maintained at 46oC to facilitate the separation 
procedure. The phenylthiocarbamyl amino acids were separated on the column during a 
90 min run, at 1 mL/min and quantified by UV absorbance at 254 nm. The peaks in the 
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chromatogram for each amino acid were integrated using Breeze Software 
(Waters,Version 3.3, 2002, Waters Corporation, Woburn MA, USA), and the amino acid 
concentrations in the plasma were determined by comparing peak areas to the area 
produced by the internal standard (norleucine). 
2.5.1.2 Fractional rates of tissue specific protein synthesis 
a. Tissue preparation 
One gram of tissue was homogenized with 3 mL of 2% perchloric acid at 50% 
speed using a mechanical homogenizer for ~45 seconds. The homogenates were 
centrifuged at 3000 g for 15 min to separate acid-soluble, tissue-free amino acids from 
acid-insoluble, protein-bound amino acids. This was repeated 3 times for the complete 
separation of tissue-free amino acids (supernatant) from the protein-bound pool.  
Tissue-free amino acids: The standard, 100 µL norleucine (25 µmol/mL) (Sigma 
Aldrich, Oakville, Canada) was added to the supernatant containing the tissue-free amino 
acids. Prior to analyzing the tissue free amino acid concentrations, 9 mL of the 
supernatant was neutralised with 375 uL of 2M K2CO3 and the samples were centrifuged 
to separate the supernatant from precipitate. One mL of filtered supernatant was dried 
down and derivatized as described above (2.5.1.1 a), with the exception that larger 
volumes of the pre-derivatization solution (TEA:water:MeOH, 100 µL) and the 
derivatization solution (TEA:water:MeOH:PITC, 50 µL) were used.  In the final step, the 
derivatized samples were re-suspended in 300 µL of sample diluent. 
Protein-bound amino acids: The internal standard, norleucine (400 µL of 25 
µmol/mL) was added to the acid-insoluble protein pellet that remained after separating 
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the tissue free component. Subsequently, the pellet was hydrolysed with 6M HCl for 24 h 
at 110oC. The resulting hydrolysate solution was cooled overnight and then diluted to 25 
mL with HPLC water. The resulting solution was filtered using 0.45 µm syringe filters 
(Life Sciences, Canada) and 1mL of the filtrate was placed in a vacuum oven until dry. 
The dried pellet was derivatized via the same method as the tissue free amino acids 
(2.5.1.2 b). 
b. HPLC and fraction collection 
Phenylalanine concentration in tissues was determined as described above for 
plasma amino acids. The radioactivity associated with tissue free and bound 
phenylalanine was determined by fraction collecting the eluent that was associated with 
the phenylalanine peak. Three minute windows were collected that were timed to 
correspond to the phenylalanine peak, which resulted in 3 mL fractions. The radioactivity 
in the phenylalanine fraction was determined by liquid scintillation counting using 
biodegradable scintillant (10 mL) (Fisher Scientific, Whitby, Canada).  
c. Calculations 
A fractional rate of tissue-specific protein synthesis (FSR) was determined using 
the following formula: 
Ks (%/day) = (S b/S a) x (1,440/t) x 100 
Where Sb is the SRA of the protein-bound, labelled amino acid, Sa is the SRA of 
the precursor pool and the t is the duration of labelling in minutes (Garlick et al, 1980). 
2.5.2Immunohistochemistry - Crypt cell proliferation Index  
a. Immunohistological staining of BrdU incorporated nuclei 
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Formalin fixed sections of jejunum were assigned with random numbers by a person 
not associated with the study. Subsequently, the sections were paraffin-embedded. A 
microtome (Thermos Scientific, USA) was used to cut 5 µm thickness sections, which 
were mounted on gelatine-coated slides that were prepared in the laboratory. Plain slides 
(Bio-nuclear Diagnostics Inc., Canada) were coated using a mixture of 0.3 g of gelatine 
(Sigma Aldrich, Oakville, Canada) in 290 mL of dH2O and 0.03 g of chromium 
potassium sulphate (Sigma Aldrich, Oakville, Canada) in 10 mL of dH2O. The mounted 
slides underwent microwave pre-treatment at 60oC overnight to make the cells permeable 
for antibody labelling of BrdU. The sections were stripped of paraffin using xylene 
(Fisher Scientific, Whitby, Canada), 100% ethanol and then 95% ethanol. The sections 
were outlined with liquid repellent slide marker pen (Daido Sangyo Ltd., Tokyo), then the 
sections were incubated with 3% H2O2 in phosphate-buffered saline (PBS) at room 
temperature for 10 minutes to inhibit endogenous peroxidase activity. After rinsing the 
slides with fresh PBS, slides were heated with antigen retrieval system at 89oC in a coplin 
jar for another 10 minutes. This procedure unmasks the antigenic sites leading to 
improved immunostaining. The slides were cooled at room temperature and rinsed 3 
times with fresh PBS before they were incubated overnight with biotin anti-BrdU 
monoclonal antibody in a humidified chamber at 4oC. The PBS-rinsed sections were 
again incubated for 1 hour with secondary antibody, streptavidin horse-radish peroxidase 
(SAv-HRP) enzyme complex (BD Biosciences, Mississauga, Canada). The resulting  
complex was stained with 3, 3'- diaminobenzidine (DAB) substrate system (Vector 
Laboratories Inc., Burlington, Canada) to visualize the BrdU labelled DNA (BrdU In-Situ 
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Detection kit, BD Pharmingen, Mississauga, Canada). The slides were counterstained 
with hematoxylin and eosin (Fisher Scientific, Whitby, Canada) and then rinsed 
thoroughly with water by allowing tap water to run through the container which held the 
slides. These slides were dehydrated using 95% and 100% ethanol, each for 10 minutes. 
Again xylene was used to clear the slides. Sections were covered with cover slips using 
permount (Fisher Scientific, Whitby, Canada). The slides were dried overnight in the 
fume hood, and were then ready for light microscopic visualization.  
b. Counting BrdU-labelled nuclei 
The crypt cell proliferation index was quantified by counting the number of BrdU 
labelled nuclei in 15 well oriented crypts, and was expressed as the percentage of total 
nuclei per crypt. This procedure was done by the author of this thesis (OCD) who 
remained blinded until the entire sample set was completed. 
2.5.3 Colourimetric analysis of plasma urea, ammonia and liver protein mass 
2.5.3.1 Plasma urea concentrations 
Plasma urea concentration was assayed on d7 plasma via colourimetric analysis 
(Quantichrome Urea Assay kit-BioAssay Systems, USA). This assay kit is designed to 
measure urea directly in biological samples without any pre-treatment. The colour 
produced by urea with chromogenic reagent was measured at 520 nm and this intensity is 
directly proportional to the urea concentration of the samples. 
2.5.3.2 Plasma ammonia concentrations 
Plasma ammonia concentration was also assayed quantitatively using enzymatic 
reduction method (Ammonia Assay Kit-Sigma Aldrich, Oakville, Canada). The d 7 
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plasma, which had been stored at -20oC, was used. The ammonia present in the plasma 
reacts with Alpha-Ketoglutarate (α-KG) and reduces NADPH in the presence of L-
glutamate dehydrogenase (GDH) to form L-glutamate and oxidized NADP+. The 
decrease in absorption (measured at 340 nm) measured after adding the enzyme is due to 
the oxidation of NADPH which is proportional to the ammonia concentration in the 
plasma.   
 
2.5.3.3 Liver protein mass 
Liver protein content was assayed by Biuret reaction as per the Biuret method 
(Gornall et al, 1949). 
2.5.4 Statistical analyses 
For most outcomes, data were analysed using one-way ANOVA.  If a significant 
outcome was determined, then treatment groups were compared by Bonferroni multiple 
comparisons test (GraphPad Prism 4, Graph Pad Software, San Diego, California, USA). 
For the blood flow measurement, data were analysed by repeated measures ANOVA for 
the whole time period and then again just for the last 3 measures when the values reached 
plateau (determined by a slope not different than zero). Plasma amino acid concentrations 
were analysed by repeated measures ANOVA using values from study days 4, 5 and 6. 
All data were expressed as mean ± SD. Data collected from the sow-fed reference group 
were not included in the statistical analyses, as they did not receive experimental diets. 
Rather, these data are presented as a range that represents the group mean ± 1 SD, and 
used for comparison purposes.    
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3.0 Results  
Over the course of the trial, three piglets did not complete the study. Two of the 
piglets that did not complete the study belonged to the first set of animals introduced to 
the study protocol, and died after the initiation of the enteral arginine infusion. The piglets 
were hyperammonemic, and post-mortem examination indicated that the gastric catheter 
had slipped out of the stomach. The catheter design and surgical procedure were modified 
to avoid this issue. These piglets were replaced by animals obtained from subsequent 
litters; thus the randomization by blocking for litters was incomplete. The third animal 
(IG-L Arg) did not complete the study because it was showing signs of hyperammonemia 
on d 7, and was euthanized prior to obtaining the final measurements. This animal was 
not replaced. The rest of the piglets used in this study were active, healthy and were 
interested in their environment during the study period 
3.1 Growth during study period  
The dietary treatments did not affect the mean weight gain of the piglets, and all 
three treatment groups gained weight at a rate that was well below the sow-fed littermates 
(Figure 3.1).  
3.2 Small intestinal morphology  
3.2.1 Small intestinal length and weight 
The mean small intestinal weight of all the experimental groups was 30 - 50% 
lower compared to the sow-fed reference animals, but the treatment groups were not 
significantly different from each other. However, the IG-H Arg piglets had significantly 
greater small intestinal length growth compared to IV-H Arg group (P = 0.04) (Table 
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3.1).Thus, the enteral infusion of high arginine partially ameliorated the small intestinal 
atrophy that was induced by TPN feeding. 
3.2.2 Jejunum crypt cell proliferation 
A sample of BrdU staining of crypt cell nuclei is presented in Figure 3.2. Neither 
the route of feeding of arginine, nor the amount fed resulted in significant differences in 
crypt cell proliferation index in the jejunum among treatment groups (Table 3.1).  
3.3 Tissue specific rates of protein synthesis and free amino acid concentrations 
3.3.1 Small intestinal proximal jejunal mucosa 
Independent of the route of delivery and the amount of arginine provided, our 
experimental treatments did not induce significant differences in the rate of mucosal 
protein synthesis. TPN feeding of arginine (IV-H Arg) resulted in a mean mucosal protein 
synthesis rate that was more than 2 SD below the SF Reference mean (Table 3.2). 
3.3.2 Liver  
Regardless of the amount of arginine provided, both groups given enteral arginine 
had significantly higher rates of liver protein synthesis compared to the IV-H Arg group 
(Table 3.2). In contrast, there was no significant difference in the tissue free arginine 
concentration in the liver between IG-H Arg and IV-H Arg groups; instead, liver free 
arginine was significantly lower in the IG-L Arg compared to IV-H Arg (Figure 3.3). 
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Figure 3.1: Daily growth rates of piglets fed intragastric high arginine (IG-H Arg), 
intragastric low arginine (IG-L Arg) or intravenous high arginine (IV-H Arg). 
Values are mean  SD, n = 6 per treatment. The box represents the sow-fed reference 
mean  1 SD, derived from a group of sow-fed piglets (n = 4) (SF Reference) that were 
littermates to the treatment groups. 
 
 
 
 
 
74 
 
 
 
Table 3.1: Small intestinal (SI) morphology at necropsy 
 
 
 
Values are means ± SD; n = 6 (all treatment groups) or 5 (SF Reference) for SI weight 
and length. For BrdU, n = 5 (IG-L Arg) or 6 (all other groups). P values were determined 
by one-way ANOVA. Groups with differing superscripts are significantly different at P < 
0.05 using Bonferroni’s multiple comparisons test. SF Reference values are derived from 
a group of sow-fed piglets that were littermates to the treatment groups. 
 
 
 
 IG-H Arg 
 
IG-L Arg 
 
IV-H Arg 
 
P value 
 
SF  Reference 
SI weight (g/kg body weight) 
17  2 16  2 15  2 0.39 28 5 
SI length (cm/kg body weight) 
164  11a 148  14
ab 141  17b 0.04 191 21 
Crypt cell proliferation index 
(% of BrdU positive cells) 
15.9  1.7 
 
12.7  4.1 
 
12.0  3.8 
 
0.13 
 
16 4 
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Figure 3.2:5-Bromo 2-deoxyuridine labelling of SI crypt cells 
Bracket indicates full crypt in proximal jejunum. Arrow indicates BrdU labelled 
nuclei (brown staining). 
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3.3.3 Kidney  
We also analysed the rate of protein synthesis in kidney tissue, however, we found 
no difference among treatment groups (Table 3.2).   
3.3.4 Skeletal muscle 
Protein synthesis in skeletal muscle sampled from gastrocnemius also was not 
affected by dietary arginine or the route of arginine delivery (Table 3.2). 
3.4 SMA blood flow 
All the experimental animals experienced a steady decline in SMA blood flow 
following surgery, during the adaptation period while being fed parenterally with 
moderate arginine-containing TPN (1.0 g/kg/d of arginine). The decline continued until 
the morning of day 4 (data not shown), at which point the test arginine infusions were 
initiated.  Blood flow further declined, irrespective of the route of arginine delivery, or 
the amount of arginine provided (Figure 3.4). The decline in blood flow reached plateau 
in all groups by 48 h after the test diets were initiated (48 h on Figure 3.4), as determined 
by a slope not different than zero by linear regression (data not shown). From 48 to 72 h 
of treatment, the mean blood flow values were significantly different among all treatment 
groups (repeated measures ANOVA, P = 0.002). IV-H Arg treatment had the smallest 
reduction in blood flow (22% lower than baseline). It is interesting that the provision of 
high arginine alone (IG-H Arg) attenuated some of the reduction of blood flow, whereas 
the IG-L Arg piglets demonstrated the greatest reduction at ~40% lower than baseline at 
study end.  
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Table 3.2: Tissue specific fractional rates of protein synthesis (%/d) 
 
 IG-H Arg 
 
IG-L Arg 
 
IV-H Arg 
 
P value SF  Reference 
range* 
Liver 130  26a 126  23a 85  22b 0.01 135 41 
Mucosa 71  14 60  28 57  17 0.4 110  23 
Gastrocnemius muscle 17  4   18  6 17  7 0.9 15  5 
Kidney 32  11 44  18 35  11 0.5 51  21 
 
Values are means ± SD. Liver and mucosa: n = 5 (IG-L Arg) or 6 per group. Kidney: n = 
3 (IG-L Arg) or 4 per group. Gastrocnemius: n = 4 (IV-H Arg) or 5per group. P values 
were determined by one-way ANOVA. Groups with differing superscripts are 
significantly different at P < 0.05 using Bonferroni’s multiple comparisons test. SF 
Reference values were derived from a group of sow-fed piglets that were littermates to 
the treatment groups. 
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Figure 3.3: Liver free arginine concentrations. Values are means ± SD; n = 5 (IG-L 
Arg) or 6 per group. P values were determined by one-way ANOVA. Groups with 
differing superscripts are significantly different at P < 0.01 using Bonferroni’s multiple 
comparisons test. The broken line within the box represents the mean  1 SD, derived 
from a group of sow-fed piglets (n = 6) (SF Reference) that were littermates to the 
treatment groups 
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Figure 3.4: Superior mesenteric artery blood flow. Data are expressed as the 
percentage of baseline, which was the mean blood flow of individual animals calculated 
from measurements during the 36 h period prior to initiation of the test diets (baseline). 
Values are means ± SD, n = 5 (IG-H Arg) or 6 (IG-L Arg, IV-H Arg) piglets per 
treatment. Data from 48 to 72 h were analyzed by repeated measures ANOVA using 
Bonferroni’s multiple comparisons test, a vs b, P < 0.05; a vs c, P < 0.01, b vs c, P < 0.05.  
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3.5 Plasma amino acids 
Plasma amino acid concentrations were highly variable among treatment groups. 
Only the significant results are presented below. The complete data set for plasma free 
amino acid concentrations is presented in Appendix I.   
3.5.1 Arginine family of amino acids  
 Enteral provision of low arginine (IG-L Arg) led to lower concentrations of 
plasma arginine compared to intravenous provision of high arginine (IV-H Arg) (Figure 
3.5). In IG-H Arg treatment, mean plasma proline was similar to the SF Reference mean 
while IG-L Arg and IV-H Arg groups were more than 1 SD above the SF Reference mean 
(Figure 3.5); however, the treatment groups were not significantly different from each 
other. Plasma ornithine concentrations were not significantly different between 
experimental groups; however mean concentrations follow the similar pattern as mean 
plasma arginine concentrations. In our animals, plasma mean citrulline concentrations 
were not differed by the treatment. 
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Figure 3.5: Plasma arginine, ornithine, proline and citrulline concentrations. Data 
are expressed as mean ± SD using plasma amino acid concentrations from d 4, 5 and 6; n 
= 6 (IG-H Arg and IG-L Arg) or 5 (IV-H Arg) per group. P values were determined by 
repeated measures ANOVA. Groups with differing superscripts are significantly different 
at P < 0.05 using Bonferroni’s multiple comparisons test. The broken line within the box 
represents the mean  1 SD derived from a group of sow-fed piglets (n = 3) (SF 
Reference) that were littermates to the treatment groups 
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3.5.2 Plasma indispensable amino acids 
In plasma, the lysine concentration was altered by the mode and the amount of 
arginine infused, as IV-H Arg group had significantly higher plasma lysine concentration 
compared to both IG groups (Figure 3.6).  Interestingly, the mean lysine concentration for 
the IG-H Arg group fell within the SF Reference range, whereas for the IV-H Arg group, 
lysine was well above the SF Reference range. Plasma histidine was significantly lower in 
the IG-H Arg group compared to IV-H Arg group; the mean value of histidine in the IG-
H Arg and IG-L Arg groups fell below or at the lower margin of the SF Reference range, 
whereas the mean histidine concentration of the IV-H Arg group was at the highest 
margin of the SF Reference range. Threonine, a major amino acid in the mucin 
component of mucus secreted in the intestine, was significantly affected by dietary 
treatment, as determined by the repeated measures ANOVA (P = 0.04), but no difference 
between groups was determined by the multiple comparisons test. The most remarkable 
differences were in the aromatic and some branched-chain amino acids. Plasma 
phenylalanine and tyrosine were significantly lower in both IG groups compared to IV-H 
Arg group. Altering the route of delivery resulted in more than five-fold and fourteen-fold 
difference in plasma mean concentrations of phenylalanine and tyrosine concentrations 
respectively, where the mean concentration of IV-H Arg group was more than seven-fold 
and three-fold higher than the SF Reference values. For branched-chain amino acids, both 
isoleucine and valine were significantly lower in IG groups compared to the IV group, 
and again were more similar to the SF Reference data, with the IV-H Arg group being 
83 
 
extremely high(more than three-fold higher than the SF Reference mean concentrations 
for both  
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Figure 3.6: Plasma indispensable amino acid concentrations. Data are expressed as 
the mean ± SD using plasma amino acid concentrations from day 4, 5 and 6; n = 6 (IG-H 
Arg and IG-L Arg), or 5 (IV-H Arg) per group. P values were determined by repeated 
measures ANOVA. Groups with differing superscripts are significantly different at P < 
0.05 using Bonferroni’s multiple comparisons test. The broken line within the box 
represents the mean  1 SD derived from a group of sow-fed piglets (n =3) (SF 
Reference) that were littermates to the treatment groups. 
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of isoleucine and valine) (Figure 3.6). It was interesting to note that plasma leucine 
concentrations did not differ among groups, despite the large differences in the other 
branched chain amino acids. 
3.6 Plasma ammonia and urea 
There was no significant difference in plasma ammonia concentration among 
treatment groups. All the values were high, including SF Reference (Figure 3.7) (~ 199 
uM) when compared to the values obtained for freshly sampled plasma from domestic 
piglets using the same TPN amino acid profile (Brunton et al, 1999). This is likely related 
to the prolonged freezer storage of our samples as opposed to assaying freshly sampled 
plasma (Brunton et al, 1999). Similarly, plasma urea concentrations were not different 
among treatments (Figure 3.8), but IV-H Arg tended to have higher mean values 
compared to the SF Reference mean value (9.8 mmol/L).  
3.7 Liver weight and protein mass 
There were no differences in liver wet weight or protein mass among experimental 
animals (Table 3.3). Interestingly, mean liver wet weights were more than two standard 
deviations higher than the SF Reference mean in all three experimental groups. There was 
a trend towards lower liver protein mass in piglets fed solely by the intravenous route 
compared to the animals fed only arginine into the gastric catheter (P = 0.09). 
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Figure 3.7: Plasma ammonia concentrations. Values are means ± SD; n = 6 (IG-H 
Arg), or 5 (IG-L Arg and IV-H Arg) per group. P values were determined by one-way 
ANOVA. The broken line within the box represents the mean  1 SD derived from a 
group of sow-fed piglets (n = 4) (SF Reference) that were littermates to the treatment 
groups 
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Figure 3.8: Plasma urea concentrations. Values are means ± SD; n = 6 (IG-H Arg), 5 
(IG-L Arg and IV-H Arg) per group. P values were determined by one-way ANOVA. The 
broken line within the box represents the mean  1 SD derived from a group of sow-fed 
piglets (n = 4) (SF Reference) that were littermates to the treatment groups 
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Table 3.3: Liver wet weight and protein mass  
 
 
 IG-H Arg IG-L Arg IV-H Arg P value SF Reference 
 
Liver weight 
g/kg of BW 
 
44 ± 3.5 
 
45 ± 7.3 
 
41 ± 8 
 
0.6 
 
33 ± 2.5 
 
Liver protein 
mg/kg of BW 
 
2943 ± 787 
 
3018 ± 944 
 
2069 ± 481 
 
0.09 
 
2378 ± 975 
 
 
Values are means ± SD; n= 6 (IG-H Arg and IV-H Arg) or 5 (IG-L Arg) per group. P 
values were determined by one-way ANOVA. SF Reference values were derived from a 
group of sow-fed piglets (n = 5) that were littermates to the treatment groups. BW – Body 
weight. 
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4.0 Discussion 
We hypothesised that lack of arginine availability for small-intestinal, first-pass 
metabolism during TPN feeding may contribute to the etiology of TPN-induced gut 
atrophy in neonates. The atrophied neonatal small intestine is likely incapable of adequate 
de novo arginine synthesis due to the lack of substrate and reduced metabolic activity. 
Thus, we were interested in the effects of infusing a high amount of arginine enterally to 
accommodate the requirement during such a physiological situation. To that end, we 
infused a high concentration of arginine either enterally or parenterally, and compared it 
to low enteral arginine to assess the effects of the arginine concentration and the route of 
delivery on small intestinal morphology, tissue protein synthesis and SMA blood flow.  
4.1 Hepatic protein synthesis in response to enteral arginine 
One of the most interesting results of our study was that changing the route of 
delivery of only one amino acid altered the rate of liver protein synthesis. We 
demonstrated significantly higher rates of liver protein synthesis in both groups given 
enteral arginine compared to the IV-H Arg group. The two major sources of amino acids 
for metabolism in the liver are extracellular from arterial and portal blood supplies and 
intracellular from protein breakdown and from intracellular metabolism. However, 
evidence from previous studies supports preferential utilization of extracellular amino 
acids as precursors for hepatic protein synthesis during the fed state (Berthold et al, 1995; 
Jahoor et al, 1994; Reeds et al, 1992; Cayol et al, 1996; Lichtenstein et al, 1990; Parhofer 
et al, 1990). In our study, there were no differences in liver free arginine concentrations 
between groups that received intragastric versus  
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intravenous arginine. The liver free arginine that we measured in our study represented 
arginine extracted from the hepatic artery, portal vein and from hepatic protein 
breakdown. Therefore, total liver free arginine likely did not contribute to the observed 
differences in liver protein synthesis in our animals.  
In a study by Stoll et al (1997), 2H-phenylalanine was infused via a peripheral 
vein and 13C-phenylalanine was given via the stomach along with a milk-replacer diet 
under steady state conditions. They found a greater ratio of 13C/2H phenylalanine in portal 
blood compared to the arterial blood. However, there was no difference between portal 
blood and plasma VLDL apoB-100 enrichments. Furthermore, the enrichment values for 
portal blood and apoB-100 were two-fold higher than the enrichments in the hepatic free 
pool. This indicated that portal phenylalanine was the preferred precursor source for the 
hepatic synthesis of secretory proteins in the fed state. In a second study by Stoll et al 
(1998b), amino acid labelling was measured in arterial and portal blood, in hepatic-free 
and protein-bound pools, and in hepatic secretory proteins. This was accomplished by 
feeding 13C-labelled algal protein, in which multiple amino acids were intrinsically 
labelled. The protein was infused intragastrically for 6 h along with a high protein diet. 
The isotopic enrichment of amino acids in apoB-100 was higher than in the respective 
hepatic-free amino acid pools. They demonstrated that dietary amino acids are the 
preferred source for hepatic constitutive and secretory protein synthesis rather than amino 
acids in the systemic circulation (Stoll et al, 1998b). Thus, Stoll et al (1997; 1998b) 
clearly showed that the portal vein amino acid pool was the preferred source for hepatic-
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origin plasma protein synthesis in the fed state. Unfortunately, we did not collect the 
plasma from the portal  
vein to measure the portal amino acid concentrations; therefore we cannot be certain that 
the gastrically infused arginine appeared in the portal vein. However, it follows that the 
intravenous delivery of arginine would result in lower portal concentrations compared to 
IG delivery, as the only net addition of arginine to portal blood must be from tissue 
protein breakdown in the complete TPN piglets. Thus, our finding that liver protein 
synthesis is greater with enterally delivered arginine is consistent with the idea that portal 
amino acids provide the amino acid precursor pool for hepatic protein synthesis; arterial 
and liver-origin amino acids seem less important since the same amount of parenteral 
arginine had a lesser effect on hepatic protein synthesis. It is interesting that only one 
amino acid could induce such an effect, and seems likely that other mechanisms are 
involved, which have not yet been identified.  
Arginine is a known secretagogue for insulin when delivered intravenously, but 
whether it affects insulin secretion following oral ingestion in neonates is not known. In 
adults, oral intake of arginine alone did not affect insulin secretion (Gannon et al, 2002). 
Therefore, if insulin was involved in stimulating protein synthesis in our model, it is more 
likely that the IV-H Arg group would have been most affected. Davis et al (2001) 
demonstrated that amino acids and insulin or insulin alone stimulated peripheral tissue 
protein synthesis in neonatal piglets, but in the liver, the effect of amino acids was 
independent of insulin. Two other recent studies with neonatal piglets have demonstrated 
that amino acids provided into the carotid artery stimulated hepatic protein synthesis and 
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that this response did not require insulin (Suryawan et al, 2009; O’Connor et al, 2004). 
Thus, our finding that intragastric arginine infusion induced hepatic protein synthesis was 
likely not mediated by insulin. 
 
4.2 Superior mesenteric artery blood flow in response to arginine 
We hypothesised that the provision of high arginine enterally would ameliorate 
the reduction of SMA blood flow that is induced by prolonged TPN feeding, via 
increased synthesis of nitric oxide. In contrast to our hypothesis, SMA blood flow further 
declined after the initiation of treatments, irrespective of the route of delivery or the 
amount of arginine provided. The decline in blood flow reached plateau approximately 48 
h after the test diets were initiated. From 48 to 72 h of treatment, mean blood flow values 
were significantly different between all treatment groups. Animals that received the low 
intragastric arginine demonstrated the greatest decline in blood flow, being ~40% lower 
than baseline at study end. Provision of the high concentration of arginine into the gastric 
catheter attenuated some of the reduction in blood flow. However, surprisingly, the 
smallest reduction in blood flow was observed in piglets given the IV-H Arg treatment. It 
is well known that fasting and TPN feeding result in the reduction of blood flow to the 
small intestine. Alternatively, an increase in blood flow is observed immediately after oral 
feeding in neonatal piglets (Van Goudoever et al, 2001). Fasting mesenteric artery blood 
flow reached a peak within one hour after feeding in term-born, healthy infants that were 
either breast-fed or bottle-fed (Coombs et al, 1992; Gladman et al, 1991). In a recent 
study of TPN-fed neonatal piglets by Puiman et al (2011), they reported almost a 
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doubling of the SMA blood flow with the initiation of partial enteral-feeding (40% of 
total intake) compared to piglets maintained on complete intravenous feeding. Moreover, 
a previous study involving chronic TPN feeding of piglets showed that 4 h following the 
transition from enteral to TPN feeding, a 50% reduction of SMA blood flow was 
observed  
(Niinikoski et al 2004). This cumulative evidence suggests that contact with luminal 
digesta or absorbed nutrients by the mucosal cells must trigger this increase in SMA 
blood flow. Infusing only arginine into the gastric catheter in the present study was not 
nearly as effective as infusing a complete diet, as the decline in blood flow continued 
following the initiation of enteral arginine.  
 Interestingly, arginine availability did play a role in mediating blood flow, as we 
observed an attenuation of SMA blood flow decline with high compared to low arginine. 
In our study, we cannot directly link arginine availability to NO synthesis.  However, in 
enterally-fed, arginine-deficient piglets, Urschel et al (2005; 2007) reported significantly 
lower whole body arginine synthesis and significantly lower nitric oxide synthesis when 
compared to piglets fed generous arginine. The proportion of arginine flux converted into 
nitric oxide was not different between groups (13%), even though the whole body 
arginine flux was significantly lower in piglets fed arginine-deficient diets (Urschel et al, 
2005; 2007). These data indicate that the capacity to synthesize nitric oxide is at least 
partially dependent on precursor availability in neonatal piglets. In our study, the best 
outcome in terms of blood flow occurred when we delivered arginine intravenously, 
despite identical intakes in the IG-H Arg and IV-H Arg groups. This finding does not 
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necessarily indicate that intragastric provision of high arginine was ineffective, or that the 
degree of intestinal atrophy is solely a consequence of reduced blood flow. It is highly 
likely that some of the arginine provided intragastrically was extracted by the splanchnic 
bed, which may have resulted in a lower concentration of precursor available in the 
superior mesenteric arterial circulation to ultimately synthesize endothelial NO. Small  
intestinal mucosal growth parameters such as crypt cell proliferation, small intestinal 
weight and mucosal fractional protein synthesis consistently tended to be higher in the 
IG-H Arg group compared to the other groups, although not significantly different. 
Indeed, none of the outcomes (either small intestinal mucosal fractional protein synthesis 
or morphological outcomes that we measured) were significantly worse in the IG-H or 
IG-L Arg groups, compared to the IV-H Arg group, despite greater reductions in blood 
flow. Thus, the utilization of enterally-delivered arginine by the intestinal mucosa was 
likely occurring in both IG-H and IG-L Arg animals, and perhaps less was getting into the 
systemic circulation. While not significantly different, plasma arginine in the IG-H Arg 
group tended to be ~23% lower than the TPN group; plasma arginine was 71% lower in 
the IG-L Arg group than TPN group, which was significantly different. Thus, it is 
possible that two things were going on that were in conflict. On one hand, reduced SMA 
blood flow might have encouraged intestinal atrophy in IG Arg groups, while luminal 
arginine availability to the intestinal mucosa was stimulating recovery.  
Recently, a study was published with a design that was quite similar to our study 
(Puiman et al, 2011) as both studies assessed the effects of arginine infused 
intragastrically to piglets with low SMA blood flow induced by TPN feeding. However, 
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the arginine protocol used was different between the two studies. Surprisingly, arginine 
infused intragastrically as the sole amino acid for three hours at more than five times the 
requirement (3.35 g/kg/d) did not induce an increase in SMA blood flow (Puiman et al, 
2011). In contrast to the Puiman study, the concentration of arginine given to our IG-H 
Arg animals was estimated to meet the requirement for  
piglets (Brunton et al, 2003), but was only 48% the concentration used in the Puiman 
study (Puiman et al, 2011). Furthermore, Puiman’s animals received the intragastric 
arginine dose over 3 h, thus a bolus dose, whereas we infused the treatments continuously 
and recorded blood flow over 3 days. The blood flow response we observed was different 
than the response measured by Puiman et al (2011) as Puiman did not find a measurable 
change in SMA blood flow. The differences in the outcomes between the two studies 
need to be interpreted with caution. If the effect of arginine as a precursor for nitric oxide 
is systemic (as opposed to local), it may take time to observe a measurable effect at the 
systemic level, especially if induction of NOS enzymes is necessary. Also, there may be a 
maximal effect; thus providing more arginine during a short period of time may not be 
beneficial. Therefore, it is possible that it takes much longer than 3 hours to produce a 
measurable difference in SMA blood flow after initiation of an intragastric infusion of 
arginine. The fact that Puiman did not see at least some stimulation of SMA blood flow in 
complete TPN-fed animals with the infusion of large amounts of arginine is likely due to 
time as a limiting factor.  
The change in SMA blood flow that is induced by full enteral feeding may be a 
systemic effect rather than a local effect. A study by Niinikoski et al, (2004) measured 
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changes in blood flow in neonatal piglets, following the re-introduction of enteral feeding.  
They found that the increase in SMA blood flow occurred much earlier than the rise in 
portal blood flow (1 vs. 4 h). They also assessed the portal blood flow during the 
transition from enteral to parenteral nutrition, in which the portal blood flow declined to 
the food-deprived level by 8 h after the transition. SMA blood flow took only 4 h to 
stabilize to the food-deprived level (Niinikoski et al,  
2004). This suggests that the change in SMA blood flow occurs more rapidly than the 
corresponding change in portal blood flow and thus may be a systemic effect rather than a 
local, post-intestinal effect. Indeed, that must be the reason why we saw the greatest 
amelioration of the reduction of SMA blood flow with complete IV feeding of high 
arginine compared to the IG-H Arg group. If it is a systemic effect rather than a local 
effect, it may be worthwhile to target arginine availability in the superior mesenteric 
arterial (SMA) circulation. We did not collect arterial blood; instead we sampled blood 
from the inferior vena cava just caudal to the heart, which is similar to arterial blood 
except for the effects of lung metabolism. In piglets, 13% of arginine flux is used for NO 
synthesis which is rather significant (Urschel 2005; 2007). In our study, the pattern of 
arginine concentrations in the three diet groups paralleled the blood flow response even 
though the plasma arginine was not significantly different among all the groups, with the 
exception of the IG-L Arg and IV-H Arg groups. The plasma arginine concentrations 
were measured in vena cava blood, which may not accurately represent the concentration 
in the SMA. However, the data from our study and the results from the Puiman et al 
(2011) suggest that both systemic availability of arginine for NO synthesis, and the 
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duration of the continuous infusion of arginine, likely contributed to the maintenance of 
SMA blood flow during TPN feeding.  
The SMA response that we observed may be attributed to the capacity of eNOS 
and the availability of arginine precursor for NOS activity in our piglets. Castillo et al 
(1996) determined that 50% of the substrate for NOS came from the plasma 
compartment, in healthy men. There is evidence of channelling of extracellular (plasma) 
arginine directly to eNOS by the arginine transporter CAT-1 (Arnal et al,  
1995; Norris et al, 1995; Bune et al, 1995). Enzyme kinetics studies have demonstrated 
that the Km of eNOS for plasma-derived arginine was 73 µm in one study (Granger et al, 
1990) and 150 µM in another study (Iyengar et al, 1987). The plasma concentration in our 
individual IG-L Arg animals ranged between 30 to 45 µM, lower than the estimated Km 
values of eNOS for extracellular arginine. Therefore, it is possible that plasma arginine 
availability, but not intracellular arginine levels, affected endothelial NO synthesis 
capacity in our IG-L Arg piglets, resulting in the lower SMA blood flow compared to the 
other two experimental groups. 
Data from the current study combined with studies by Puiman et al (2011) and 
Niinikoski et al (2004) suggest that arginine alone could not induce the magnitude of 
response that is stimulated by full feeding enterally. Thus, other factors may explain the 
muted response of intragastric arginine on SMA blood flow. TretrahydrobiopterinBH4 is 
an essential cofactor for the activity of all NOS isoforms and is synthesized in endothelial 
cells. Arginine can stimulate an increase in BH4 synthesis (Wu & Meininger, 2009); thus, 
greater arginine in endothelial cells would result in greater availability of BH4. Therefore, 
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NO production by NOS may be lower due to reduced availability of BH4 in endothelial 
cells in our IG Arg piglets.  
4.3 Plasma and tissue free indispensable amino acids  
In the present study, a pattern emerged of higher plasma indispensable amino 
acids in the group of piglets fed solely by TPN compared to the sow-fed reference group. 
In contrast, the mean values for the two intragastric groups were generally within the 
sow-fed range. The amino acid intakes for the IG-H Arg and the IV-H Arg groups were 
identical; thus, differences in the plasma amino acid pools could only be  
the result of the route of feeding of one amino acid. Bertolo et al (2000) reported a 
number of differences in plasma amino acid concentrations in piglets fed an identical diet 
intravenously, intragastrically or intraportally. Furthermore, they observed differences in 
organ amino acid concentrations in the same study, suggesting that the route of feeding 
alters the plasma and organ amino acid concentrations. We also observed significantly 
higher liver free phenylalanine and valine concentrations in IV-H Arg piglets compared to 
the IG groups. The liver free phenylalanine concentration was well outside the sow-fed 
reference range in IV-H Arg piglets. In total, these findings support the idea that there is 
either greater protein breakdown or less amino acid utilization, or both occurring in the 
IV-H Arg piglets. Remarkably, the provision of only arginine into the gut partially 
“normalized” the plasma profile of many indispensable amino acids in our animal model. 
Thus, an important finding from this study is that enterally-delivered arginine induced a 
response in plasma amino acids similar to the response induced by complete or partial 
enteral feeding.  
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4.4 Small intestinal morphology  
In our study, the enteral provision of arginine at 1.6 g/kg/d resulted in greater 
length of the small intestine, compared to a similar intake provided parenterally. 
However, none of the other small intestinal morphological characteristics that we 
measured (small intestinal weight, crypt cell proliferation, and mucosal protein synthesis) 
reached statistical significance between treatments. Bertolo et al (1999a & b) reported 
that feeding identical elemental diets via intragastric, intraportal or intravenous routes did 
not affect small intestinal length in neonatal piglets over an 8 day feeding period, 
suggesting that small intestinal atrophy is not characterised by  
reduced small intestinal length growth. Thus, it was surprising that enteral arginine 
facilitated greater small intestinal length, and no other morphological outcome in our 
model. To my knowledge, our study is the first to investigate mucosal growth specifically 
in response to an enteral arginine infusion in TPN-fed neonatal piglets with gut atrophy. 
A similar study conducted by Puiman et al (2011) investigated the effects of providing a 
supra-physiological concentration of arginine with partial enteral (PEN) feeding (20%) in 
neonatal piglets fed for 3 days.  They demonstrated greater proximal small intestinal 
mucosal mass, protein mass and DNA mass when the enteral infusate was supplemented 
with 3.34 g/kg/d of arginine, compared to animals given alanine as a control. The fact that 
PEN stimulates mucosal growth is well recognized from an earlier study by this group 
(Burrin et al, 2000); 60% of total intake was required to maximise intestinal growth. This 
time however, they provided only 20% of nutrients enterally along with more than twice 
the daily arginine requirement (Puiman et al, 2011). Despite a number of differences in 
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morphological outcomes, they found no significant effect of arginine on mucosal protein 
synthesis or crypt cell proliferation, similar to our findings. Thus, our results combined 
with those of Puiman et al (2011), suggest that the enteral arginine has a role in 
stimulating recovery from TPN-induced intestinal atrophy, but more than 20% of total 
intake enterally is likely necessary along with high arginine. In our model, the lack of 
enteral amino acids and other nutrients explains why we did not see significant 
morphological differences. The design of our model was such that we did not expect to 
see major morphological differences; rather, it was a design that might allow us to isolate 
potential effects of arginine from that of other trophic factors.  
4.5 Indicators of whole body arginine adequacy: plasma ammonia, urea and 
arginine concentrations  
There were no significant differences in plasma urea or ammonia concentrations 
between treatment groups. However, the mean urea concentration in the piglets that did 
not receive enteral arginine was well above the sow-fed reference mean; in contrast, the 
mean plasma urea concentrations in the IG Arg groups were similar to sow-fed reference 
mean. It is possible that there was greater catabolism of amino acids ongoing in the IV-H 
Arg group, because of inefficient utilization for protein synthesis; alternatively, excess 
amino acids may have accumulated from protein breakdown in the IV-H Arg group. In 
support of this, we also observed significantly higher concentrations of some of the 
plasma indispensable amino acids in our IV-H Arg piglets compared to IG-H and IG-L 
Arg groups. No difference in plasma ammonia concentrations among groups indicated 
that even with the low intake of 0.6 g arginine/kg/d intragastrically, the urea cycle 
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requirements were met. In contrast, the IG-L Arg piglets had a mean plasma arginine 
concentration that was only one-third that of the SF Reference piglets, clearly indicating 
that 0.6 g/kg/d of arginine delivered enterally did not fulfill the total body arginine 
requirement. Plasma urea measured in our sow-fed 20 d old Yucatan miniature pigs was 
9.8 ± 5mM (mean ± SD). Another recent study in our lab determined that the plasma urea 
concentration was much lower, at 5.3 ± 0.9 mM (mean ± SD) in 17 - 19 d old TPN fed 
neonatal piglets (Brunton et al, unpublished data). The high urea values in the current 
study may be because the plasma samples underwent freeze-thaw cycles during storage. 
Therefore the absolute values are suspicious.  
 
4.6 Liver morphology: liver weight and protein mass 
A noteworthy observation was the higher liver weights in all our experimental 
animals, compared to the SF Reference group, suggesting hepatic steatosis which is 
common in TPN feeding (Wang et al, 2006).  There was no difference in the total liver 
protein content, despite significantly higher liver protein synthesis in the IG-H Arg 
compared to IV-H Arg piglets; this may be due in part to the secretion of newly 
synthesized hepatic proteins from liver. It is also possible that there were differences in 
liver composition, with greater lipid deposition in the IV-H Arg. However, we did not 
analyse liver water or lipid content in these animals.  
4.7 Growth and the composition of growth  
We measured the growth rate by means of weight gain per day and skeletal 
muscle protein synthesis. We did not see differences in growth rate related to arginine 
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intake, or route of infusion. Similar to our findings, most neonatal piglet studies have 
found that route of diet delivery did not alter the absolute weight gain during the period of 
study (Bertolo et al, 1999a& b; Burrin et al, 2000), with the exception of a recent study by 
Stoll et al (2010), that reported significantly higher daily body weight in enterally-fed 
piglets, over a 17 d feeding trial. According to Stoll et al (2010), TPN-feeding resulted in 
greater fat mass and lesser lean and bone mass compared to enterally fed piglets. 
Therefore, it is important to consider that absolute growth rates are difficult to interpret 
during short-term feeding trials.  
In the present study, neither intragastric nor intravenous arginine stimulated 
greater skeletal muscle protein synthesis. The skeletal muscle fractional protein synthesis 
rates for all the experimental groups were within the range of the sow-reared  
reference group, but interestingly, the overall weight gain per day was below that of the 
sow-reared piglets. Brunton et al (2003) reported that skeletal muscle protein synthesis 
increased with increasing provision of arginine in intravenously-fed piglets. We 
hypothesized that muscle protein synthesis would be higher in our IG-H Arg and IV-H 
Arg fed animals compared to IG-L Arg piglets, because the intake by the IG-L Arg was 
estimated to be below the estimated whole body requirement. However, we did not see 
such a difference in the present study.  
4.8 Discussion of the model 
We infused only arginine (dissolved in HPLC water) into the gastric catheter in 
two groups of piglets, to isolate the specific effects of arginine on intestinal atrophy. 
When deciding on the model, we were cognizant of the fact that providing just arginine 
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alone would not maximize a response. The lack of many other essential dietary factors 
those are normally available in full or partial enteral feeding limited the potential trophic 
effect of intragastric arginine. This may be the reason that we did not see significant 
differences for some of the outcomes, but observed many “trends” suggesting an effect of 
enteral arginine.  
5.0 Conclusions 
The objective of our study was to determine whether arginine, delivered as a 
single nutrient into the small intestine, would act as a trophic factor and attenuate some of 
the features of small intestinal atrophy that accompany TPN feeding. We were the first to 
demonstrate that the delivery of arginine alone into a gastric catheter, irrespective of the 
amount provided, stimulated hepatic protein synthesis. By contrast, the provision of 
arginine enterally was not as effective as the parenteral delivery of  
arginine to ameliorate the reduction of SMA blood flow, thus suggesting the importance 
of adequate arginine at the systemic level. Despite a greater sustained blood flow in the 
IV-H Arg piglets, none of the other small intestinal outcomes were significantly 
enhanced. Therefore, the greater SMA blood flow induced by high intravenous arginine 
did not translate into significant growth-promoting effects in the small intestine. In fact, 
provision of arginine into the gut must have provided an advantage since the IG Arg 
piglets sustained small intestinal morphology that was comparable to the IV-H Arg 
piglets, despite lower SMA blood flow. Finally, and perhaps the most interesting 
outcome, was the fact that the enteral delivery of only arginine along with TPN resulted 
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in a plasma amino acid profile in which a number of indispensable amino acids were 
“normalized” relative to sow-fed piglets, indicating a profound metabolic effect.  
We are currently working to replace minimum enteral feeding (60% of TPN) in 
the clinical setting with a single or few amino acids which might have potential trophic 
effects on gut atrophy. In neonatal piglets, we have shown that enteral arginine alone has 
partial trophic effect on the amelioration of gut atrophy induced by prolonged TPN 
feeding. It is possible that some other amino acids with or without arginine might also 
have trophic effects on gut atrophy, thus warranting further studies. Since the early 
introduction of minimal enteral nutrition is not always possible, it is important to identify 
therapies that could replace challenging minimal enteral nutrition in clinical settings.  
 
 
 
 
REFERENCES 
 
1. Alican I, Kubes PA. (1996) Critical role for nitric oxide in intestinal barrier 
function and dysfunction. Am J Physiol. 270: G225–G237. 
2. Alp NJ, Channon KM. (2004) Regulation of endothelial nitric oxide synthase by 
tetrahydrobiopterin in vascular disease. ArteriosclerThrombVasc Biol. 24(3):413-
20.  
3. Alp NJ, Mussa S, Khoo J, Cai S, Guzik T, Jefferson A, Goh N, Rockett KA, 
Channon KM. (2003) Tetrahydrobiopterin-dependent preservation of nitric oxide-
mediated endothelial function in diabetes by targeted transgenic GTP-
cyclohydrolase I overexpression. J Clin Invest. 112:725–35. 
4. Altman PL, Dittmer DS. (1962) Growth including reproduction and morphological 
development. Fed Am SocExpBioI. 608. 
5. Amin HJ, Zamora SA, McMillan DD, Fick GH, Butzner JD, Parsons HG, Scott 
RB. (2002) Arginine supplementation prevents necrotizing enterocolitis in the 
premature infant. J Pediatr. 140(4):425-31. 
6. Arnal JF, Münzel T, Venema RC, James NL, Bai CL, Mitch WE, Harrison DG. 
(1995) Interactions between L-arginine and L-glutamine change endothelial NO 
106 
 
production. An effect independent of NO synthase substrate availability. J Clin 
Invest. 95(6):2565-72. 
7. Batshaw ML, Wachtel RC, Thomas GH, Starrett A, Brusilow SW. (1984) 
Arginine-responsive asymptomatic hyperammonemia in the premature infant. J 
Pediatr. 105:86-91. 
8. Becker RM, Wu G, Galanko JA, Chen W, Maynor AR, Bose CL, Rhoads JM. 
(2000) Reduced serum amino acid concentrations in infants with necrotizing 
enterocolitis. J Pediatr. 137(6):785-93. 
9. Bengmark S, Gianotti L. (1996) Nutritional support to prevent and treat multiple 
organ failure. World J Surg. 20(4):474-81. 
10. Berthold HK, Jahoor F, Klein PD, Reeds PJ. (1995) Estimates of the effect of 
feeding on whole-body protein degradation in women vary with the amino acid 
used as tracer. JNutr. 125(10):2516-27. 
11. Bertolo RF, Burrin DG. (2008) Comparative aspects of tissue glutamine and 
proline metabolism. J Nutr. 138: 2032S–2039S. 
12. Bertolo RF, Chen CZ, Law G, Pencharz PB, Ball RO. (1998) Threonine 
requirement of neonatal piglets receiving total parenteral nutrition is considerably 
lower than that of piglets receiving an identical diet intragastrically. J Nutr. 128: 
1752–1759. 
13. Bertolo RF, Pencharz PB, Ball RO. (1999a) A Comparison of parenteral and 
enteral feeding in neonatal piglets, including an assessment of the utilization of a 
glutamine-rich, pediatric elemental diet. J Parenter Enteral Nutr.23:47-55. 
14. Bertolo RF, Chen CZ, Pencharz PB, Ball RO. (1999b) Intestinal atrophy has a 
greater impact on nitrogen metabolism than liver by-pass in piglets fed identical 
diets via gastric, central venous or portal venous routes. J Nutr. 129(5):1045-52. 
15. Bertolo RF, Pencharz PB, Ball RO. (2000) Organ and plasma amino acid 
concentrations are profoundly different in piglets fed identical diets via gastric, 
central venous or portal venous routes. J Nutr. 130(5):1261-6. 
16. Bertolo RF, Brunton JA, Pencharz PB, Ball RO. (2003) Arginine, ornithine, and 
proline interconversion is dependent on small intestinal metabolism in neonatal 
pigs. Am J Physiol Endocrinol Metab. 284:E915–22. 
17. Bidlingmeyer BA, Cohen SA, Tarvin TL. (1984) Rapid analysis of amino acids 
using pre-column derivatization. J Chromatogr. 336:93–104. 
18. Blachier F, Selamnia M, Robert V, M'Rabet-Touil H, Duée PH.(1995) Metabolism 
of L-arginine through polyamine and nitric oxide synthase pathways in 
proliferative or differentiated human colon carcinoma 
cells.BiochimBiophysActa.1268(3):255-62. 
19. Bohlen HG. (1980) Intestinal tissue PO2 and microvascular responses during 
glucose exposure. Am J Physiol. 238(2):H164-71. 
20. Brosnan JT. (2003) Interorgan amino acid transport and its regulation. J 
Nutr.133:2068S-2072S. 
21. Brosnan JT, Wijekoon EP, Warford-Woolgar L, Trottier NL, Brosnan ME, 
Brunton JA, Bertolo RF. (2009) Creatine synthesis is a major metabolic process in 
107 
 
neonatal piglets and has important implications for amino acid metabolism and 
methyl balance. J Nutr. 139(7):1292-7.  
22. Brunton JA, Bertolo RF, Pencharz PB, Ball RO. (1999) Proline ameliorates 
arginine deficiency during enteral but not parenteral feeding in neonatal piglets. 
Am J Physiol. 277:E223–31. 
23. Brunton JA, Ball RO, Pencharz PB. (2000) Current total parenteral nutrition 
solutions for the neonate are inadequate. CurrOpinClinNutrMetab Care. 3: 299–
304.  
24. Brunton JA, Bertolo RF, Pencharz PB, Ball RO. (2003) Neonatal piglets with 
small intestinal atrophy fed arginine at concentration 100 to 300% of NRC were 
arginine deficient. In: 9th International Symposium on Digestive Physiology in 
Pigs. 2, Short Communications: 210–2. 
25. Bune A J, Shergill J K, Cammack R, Cook HT. (1995) L-Arginine depletion by 
arginase reduces nitric oxide production in endotoxic shock: an electron 
paramagnetic resonance study. J Fed EurBiochSociLett. 366: 127–130 
26. Burrin DG, Stoll B, Jiang R, Chang X, Hartmann B, Holst JJ, Greeley GHJ, Reeds 
PJ. (2000) Minimal enteral nutrient requirements for intestinal growth in neonatal 
piglets: how much is enough? Am J ClinNutr. 71: 1603-1610. 
27. Burrin DG, Stoll B, Chang X, Van Goudoever JB, Fujii H, Hutson SM, Reeds PJ. 
(2003) Parenteral nutrition results in impaired lactose digestion and hexose 
absorption when enteral feeding is initiated in infant pigs. Am J ClinNutr. 
78(3):461-70. 
28. Buts JP, De Keyser N, De Raedemaeker L, Collette E, Sokal EM. (1995) 
Polyamine profiles in human milk, infant artificial formulas, and semi-elemental 
diets. J Pediatr Gastroenterol Nutr. 21 (1): 44-9. 
29. Castillo L, Chapman TE, Yu YM, Ajami A, Burke JF, Young VR. (1993a) Dietary 
arginine uptake by the splanchnic region in adult humans. Am J Physiol. 
265:E532-9. 
30. Castillo L, deRojas TC, Chapman TE, Vogt J, Burke JF, Tannenbaum SR, Young 
VR. (1993b) Splanchnic metabolism of dietary arginine in relation to nitric oxide 
synthesis in normal adult man. ProcNatlAcadSci U S A.90(1):193-7. 
31. Castillo L, Ajami A, Branch S, Chapman TE, Yu YM, Burke JF, Young VR. 
(1994) Plasma arginine kinetics in adult man: response to an arginine-free diet. 
Metabolism. 43(1):114-22. 
32. Castillo L, DeRojas-Walker T, Yu YM, Sanchez M, Chapman TE, Shannon D, 
Tannenbaum S, Burke JF, Young VR. (1995) Whole body arginine metabolism 
and nitric oxide synthesis in newborns with persistent pulmonary hypertension. 
Pediatr Res. 38(1):17. 
33. Castillo L, Beaumier L, Ajami AM, Young VR. (1996) Whole body nitric oxide 
synthesis in healthy men determined from [15N] arginine-to-[15N] citrulline 
labelling. ProcNatlAcadSci U S A. 93(21):11460-5. 
34. Cayol M, BoirieY, Prugnaud J, Gachon P, Beaufrère B, Obled C. (1996) Precursor 
pool for hepatic protein synthesis in humans: effects of tracer route infusion and 
dietary proteins. Am J Physiol. 270:E980 –7.  
108 
 
35. Chapman KP, Courtney-Martin G, Moore AM, Ball RO, Pencharz PB. (2009) 
Threonine requirement of parenterally fed postsurgical human neonates. Am J 
ClinNutr. 89(1):134-41.  
36. Chapman KP, Courtney-Martin G, Moore AM, Langer JC, Tomlinson C, Ball 
RO, Pencharz PB.(2010) Lysine requirement in parenterally fed postsurgical 
human neonates. Am J ClinNutr. 91:958–65. 
37. Cheng ZB, Li DF, Ge CR, Xing JJ. (2006) Polyamines in sow colostrum and milk 
at different stages of lactation. Animal Science. 82 (1): 95-99. 
38. Chou CC, Hsieh CP, Yu YM, Kvietys P, Yu LC, Pittman R, Dabney JM. (1976) 
Localization of mesenteric hyperemia during digestion in dogs.Am J Physiol. 
230(3):583-9. 
39. Chou CC, Kvietys P, Post J, Sit SP. (1978) Constituents of chime responsible for 
postprandial intestinal hyperemia. Am J Physiol. 235(6):H677-82. 
40. Conour JE, Ganessunker D, Tappenden KA, Donovan SM, Gaskins HR. (2002) 
Acidomucin goblet cell expansion induced by parenteral nutrition in the small 
intestine of piglets. Am J Physiol. 283: G1185–G1196. 
41. Coombs RC, Morgan ME, Durbin GM, Booth IW, McNeish AS. (1992) Doppler 
assessment of human neonatal gut blood flow velocities: postnatal adaptation and 
response to feeds. J Pediatr Gastroenterol Nutr. 15(1):6-12.  
42. Courtney-Martin G, Chapman KP, Moore AM, Kim JH, Ball RO, Pencharz PB. 
(2008) Total sulfur amino acid requirement and metabolism in parenterally fed 
postsurgical human neonates. Am J ClinNutr. 88:115–24. 
43. Cynober LA. (2002) Plasma amino acid levels with a note on membrane transport: 
characteristics, regulation, and metabolic significance. Nutrition. 18(9):761-6. 
44. Dardevet D, Kimball SR, Jefferson LS, Cherrington AD, Rémond D, DiCostanzo 
CA, Moore MC. (2008) Portal infusion of amino acids is more efficient than 
peripheral infusion in stimulating liver protein synthesis at the same hepatic amino 
acid load in dogs. Am J ClinNutr. 88(4):986-96.  
45. Davis TA, Nguyen HV, Garcia-Bravo R, Fiorotto ML, Jackson EM, Lewis DS, 
Lee DR, Reeds PJ. (1994) Amino acid composition of human milk is not unique. J 
Nutr.124:1126–32. 
46. Davis TA, Fiorotto ML, Nguyen HV, Burrin DG. (1999) Aminoacyl-tRNA and 
tissue free amino acid pools are equilibrated after a flooding dose of phenylalanine. 
Am J Physiol. 277: E103–E109.  
47. Davis TA, Fiorotto ML, Beckett PR, et al. (2001) Differential effects of insulin on 
peripheral and visceral tissue protein synthesis in neonatal pigs. Am J Physiol 
Endocrinol Metab. 280:E770–E779.  
48. Dayoub H, Achan V, Adimoolam S, Jacobi J, Stuehlinger MC, Wang BY, Tsao 
PS, Kimoto M, Vallance P, Patterson AJ, Cooke JP. (2003) 
Dimethylargininedimethylaminohydrolaseregulatesnitricoxidesynthesis: genetic 
and physiologicalevidence. Circulation. 108(24):3042-7.  
49. Devés R, Boyd CA. (1998) Transporters for cationic amino acids in animal cells: 
discovery, structure, and function. Physiol Rev.78(2):487-545. 
109 
 
50. Dhanakoti SN, Brosnan JT, Herzberg GR, Brosnan ME. (1990) Renal arginine 
synthesis: studies in vitro and in vivo. Am J Physiol. 259:E437-42. 
51. Di Lorenzo M & Krantis A. (2001) Altered nitric oxide production in the 
premature gut may increase susceptibility to intestinal damage in necrotizing 
enterocolitis. J Pediatr Surg. 36: 700–705. 
52. Di Lorenzo M, Bass J, Krantis A. (1995) Use of L-arginine in the treatment of 
experimental necrotizing enterocolitis. J Pediatr Surg. 30:235–40. 
53. Dudgeon DL, Spoon D, Randall P. (1981) The effects of gastric hyperosmotic 
glucose feedings on regional perfusion in the neonatal piglet. J Pediatr Surg. 
16(6):854-8. 
54. Dudley MA, Wykes LJ, Dudley Jr AW, Burrin DG, Nichols BC, Rosenberger J, 
JahoorF, Heird WC, Reeds PJ. (1998) Parenteral nutrition selectively decreases 
protein synthesis in the small intestine. Am J Physiol 274:G131–G137. 
55. Elango R, Pencharz PB, Ball RO. (2002) The branched-chain amino acid 
requirement of parenterally fed neonatal piglets is less than the enteral 
requirement. J Nutr. 132:3123–9. 
56. Fan M Z, Stoll B, Jiang R & Burrin D G. (2001) Enterocyte digestive enzyme 
activity along the crypt-villus and longitudinal axes in the neonatal pig small 
intestine. J Anim Sci. 79: 371–381.  
57. Ford H, Watkins S, Reblock K, Rowe M. (1997) The role of inflammatory 
cytokines and nitric oxide in the pathogenesis of necrotizing enterocolitis. J 
PediatrSurg. 32: 275-82. 
58. Gannon MC, Nuttall JA, Nuttall FQ. (2002) Oral arginine does not stimulate an 
increase in insulin concentration but delay glucose disposal. Am J ClinNutr. 76: 
1016 – 1022.  
59. Garlick PJ, McNurlan MA, Preedy VR. (1980) A rapid and convenient technique 
for measuring the rate of protein synthesis in tissues by injection of [3H] 
phenylalanine. Biochem J. 192: 719–723.  
60. Garvey EP, Oplinger JA, Furfine ES, Kiff RJ, Laszlo F, Whittle BJ, et al. (1997) 
1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-
oxide synthase in vitro and in vivo. J BiolChem. 272:4959-63. 
61. Gladman G, Sims DG, Chiswick ML. (1991) Gastrointestinal blood flow velocity 
after the first feed. Arch Dis Child. 66: 17–20.  
62. Goldstein RM, Hebiguchi T, Luk GD, Taqi F, Guilarte TR, Franklin FA Jr, 
Niemiec PW, Dudgeon DL. (1985) The effects of total parenteral nutrition on 
gastrointestinal growth and development. J Pediatr Surg.20(6):785-91. 
63. Gookin JL, Rhoads JM, Argenzio R A. (2002) Inducible nitric oxide synthase 
mediates early epithelial repair of porcine ileum. Am J Physiol.283: G157–G168. 
64. Gornall AG, Bardawill CJ, David MM. (1949) Determination of serum proteins by 
means of the biuret reaction. J Biol Chem. 177(2):751-66. 
65. Granger DL, Hibbs JB Jr, Perfect JR, Durack DT. (1990) Metabolic fate of L-
arginine in relation to microbiostatic capability of murine macrophages. J Clin 
Invest. 85 (1): 264-73. 
110 
 
66. Hay WW Jr. (2008) Strategies for feeding the preterminfant. Neonatology. 
94(4):245-54.  
67. Heird WC, Nicholson JF, Driscoll JM Jr, Schullinger JN, Winters RW. (1972) 
Hyperammonemia resulting from intravenous alimentation using a mixture of 
synthetic l-amino acids: a preliminary report. J Pediatr. 81(1):162-5. 
68. Homer K and Wanstall J. (2000) Cyclic GMP-independent relaxation of rat 
pulmonary artery by spermine NONOate, a diazeiumdiolate nitric oxide donor. Br 
J Pharmacol. 4: 673. 
69. House JD, Pencharz PB, Ball RO. (1997a) Tyrosine kinetics and requirement 
during total parenteral nutrition in the neonatal piglet: the effect of glycyl-L-
tyrosine supplementation. Pediatr Res. 41:575–583b. 
70. House JD, Pencharz PB, Ball RO. (1997b) Phenylalanine requirements determined 
by using L-[1- 14C]phenylalanine in neonatal piglets receiving total parenteral 
nutrition supplemented with tyrosine. Am J ClinNutr. 65:984–993a 
71. House JD, Pencharz PB, Ball RO. (1998) Lysine requirement of neonatal piglets 
receiving total parenteral nutrition as determined by oxidation of the indicator 
amino acid L-[1-C-14]phenylalanine. Am J ClinNutr. 67: 67–73. 
72. Iyengar R, Stuehr DJ, Marletta MA. (1987) Macrophage synthesis of nitrite, 
nitrate, and N-nitrosamines: precursors and role of the respiratory burst. 
ProcNatlAcadSci U S A. 84 (18): 6369-73. 
73. Jahoor F, Burrin DG, Reeds PJ, Frazer M. (1994) Measurement of plasma protein 
synthesis rate in infant pig: an investigation of alternative tracer approaches. Am J 
Physiol. 267:R221-7. 
74. Johnson LR. (1988) Regulation of gastrointestinal mucosal growth. Physiol Rev. 
68(2):456-502. 
75. Jones ME. (1985) Conversion of glutamate to ornithine and proline: pyrroline-5-
carboxylate, a possible modulator of arginine requirements. J Nutr. 115:509–15. 
76. Kansagra K, Stoll B, Rognerud C, Niinikoski H, Ou CN, Harvey R, Burrin D. 
(2003) Total parenteral nutrition adversely affects gut barrier function in neonatal 
piglets.Am J PhysiolGastrointest Liver Physiol. 285(6):G1162-70.  
77. Kashyap S, Schulze KF, Forsyth M, Dell RB, Ramakrishnan R, Heird WC.  (1990) 
Growth, nutrient retention, and metabolic response of low-birth-weight infants fed 
supplemented and unsupplemented preterm human milk. Am J ClinNutr. 
52(2):254-62.  
78. Kawamoto S, Ishida H, Mori M, Tatibana M. (1982) Regulation of N-
acetylglutamate synthetase in mouse liver. Postprandial changes in sensitivity to 
activation by arginine. Eur J Biochem. 123(3):637-41. 
79. Kelly D, King TP, Brown DS, McFadyen M. (1991) Polyamine profiles of porcine 
milk and of intestinal tissue of pigs during suckling. ReprodNutr Dev. 31:73-80. 
80. Kim SW, Wu G. (2004) Dietary arginine supplementation enhances the growth of 
milk-fed young pigs. J Nutr. 134(3):625-30. 
81. Kohler ES, Sankaranarayanan S, Ginneken CJV, Dijk PV, Vermeulen JLM, Ruijter 
JM, Lamers WH, Bruder E. (2008) The human neonatal small intestine has the 
111 
 
potential for arginine synthesis. Developmental changes in the expression of 
arginine-synthesizing and catabolizing enzymes. BMC Developmental 
Biology.8:107.  
82. Kohli R, Meininger CJ, Haynes TE, Yan W, Self JT, Wu G. (2004) Dietary L-
arginine supplementation enhances endothelial nitric oxide synthesis in 
streptozotocin-induced diabetic rats. J Nutr. 134(3):600-8. 
83. Kvietys PR, Gallavan RH, Chou CC. (1980) Contribution of bile to postprandial 
intestinal hyperemia. Am J Physiol.238: G284. 
84. Lichtenstein AH, Cohn JS, Hachey DL, Millar JS, Ordovas JM, Schaefer EJ. 
(1990) Comparison of deuterated leucine, valine, and lysine in the measurement of 
human apolipoprotein A-I and B-100 kinetics. J Lipid Res. 31(9):1693-701. 
85. Ligthart-Melis GC, van de Poll MC, Dejong CH, Boelens PG, Deutz NE, van 
Leeuwen PA. (2007) The route of administration (enteral or parenteral) affects the 
conversion of isotopically labelled L-[2-15N] glutamine into citrulline and arginine 
in humans. J Parenter Enteral Nutr. 31(5):343-48; discussion 349-50. 
86. Ligthart-Melis GC, van de Poll MC, Boelens PG, Dejong CH, Deutz NE, van 
Leeuwen PA. (2008) Glutamine is an important precursor for de novo synthesis of 
arginine in humans. Am J ClinNutr. 87(5):1282-9. 
87. Matheson PJ, Wilson MA, Garrison RN. (2000) Regulation of intestinal blood 
flow. J Surg Res. 93(1):182-96. 
88. Marini JC, Didelija IC, Castillo L, Lee B. (2010) Plasma arginine and ornithine are 
the main citrulline precursors in mice infused with arginine-free diets. J Nutr. 140 
(8): 1432–7. 
89. Marini JC. (2012) Arginine and ornithine are the main precursors for citrulline 
synthesis in mice. J Nutr. 142(3):572-80.  
90. Morris SM Jr, Kepka-Lenhart D, Chen LC. (1998) Differential regulation of 
arginases and inducible nitric oxide synthase in murine macrophage cells. Am J 
Physiol.275:E740-7.  
91. Moughan PJ, Birtles MJ, Cranwell PD, Smith WC, Pedraza M. (1992) The piglet 
as a model animal for studying aspects of digestion and absorption in milk-fed 
human infants. World Rev Nutr Diet. 67:40–113.  
92. Myrie SB, macKay DS, Van Vliet BN, Bertolo RF. (2011) Early programming of 
adult blood pressure in the low birth weight Yucatan miniature pig is exacerbated 
by a post–weaning high-salt-fat-sugar diet. British Journal of Nutrition. In Press. 
93. Nankervis CA, Dunaway DJ, Nowicki PT. (2001) Determinants of terminal 
mesenteric artery resistance during the first postnatal month. Am J Physiol. 
280:G678-86. 
94. National Research Council. (1998) Nutrient Requirements of Swine (10thed). 
Washington, DC: National Academy Press. 
95. Niinikoski H, Stoll B, Guan X, Kansagra K, Lambert BD, Stephens J, Hartmann B, 
Holst JJ, Burrin DG. (2004) Onset of small intestinal atrophy is associated with 
reduced intestinal blood flow in TPN-fed neonatal piglets. J Nutr. 134:1467–74. 
96. Norris K A, Schrimpf J E, Flynn J L, Morris S M. (1995) Enhancement of 
macrophage microbicidal activity: supplemental arginine and citrulline augment 
112 
 
nitric oxide production in murine peritoneal macrophages and promote intracellular 
killing of Trypanosomacruzi. Infect Immun. 63: 2793–2796 
97. Nowicki PT, Caniano DA, Hammond S, Giannone PJ, Besner GE, Reber KM, 
Nankervis CA (2007) Endothelial nitric oxide synthase in human intestine resected 
for necrotizing enterocolitis. J Pediatr. 150:40-45. 
98. O’Connor PMJ, Bush JA, Suryawan A, Nguyen HV, and Davis TA. (2003a) 
Insulin and amino acids independently stimulate skeletal muscle protein synthesis 
in neonatal pigs. Am J PhysiolEndocrinolMetab. 284: E110–E119. 
99. O’Connor PMJ, Kimball SR, Suryawan A, Bush JA, Nguyen HV, Jefferson LS, 
and Davis TA. (2003b)Regulation of translation initiation by insulin and amino 
acids in skeletal muscle of neonatal pigs. Am J PhysiolEndocrinolMetab. 285: 
E40–E53. 
100. O'Connor PMJ, Kimball SR, Suryawan A, Bush JA, Nguyen HV, Jefferson LS, 
Davis TA. (2004) Regulation of neonatal liver protein synthesis by insulin and 
amino acids in pigs. Am J PhysiolEndocrinolMetab. 286(6):E994-E1003.  
101. Parhofer KG, Hugh P, Barrett R, Bier DM, Schonfeld G. (1991) Determination of 
kinetic parameters of apolipoprotein B metabolism using amino acids labelled with 
stable isotopes. J Lipid Res. 32(8):1311-23.  
102. Pollock JS, Förstermann U, Mitchell JA, Warner TD, Schmidt HH, Nakane M, 
Murad F. (1991) Purification and characterization of particulate endothelium-
derived relaxing factor synthase from cultured and native bovine aortic endothelial 
cells. ProcNatlAcadSci U S A. 88(23):10480-4.  
103. Pond WG, Houpt KA. (1978) The Biology of the Pig. Ithaca, NY: Comstock. 31a. 
104. Pond WG, Houpt KA. (1978) The Biology of the Pig. Ithaca, NY: Comstock. 
371b. 
105. Puiman PJ, Stoll B, van Goudoever JB, Burrin DG. (2011) Enteral arginine does 
not increase superior mesenteric arterial blood flow but induces mucosal growth in 
neonatal pigs. J Nutr. 141(1):63-70.  
106. Quirós-Tejeira RE, Ament ME, Reyen L, Herzog F, Merjanian M, Olivares-
Serrano N, Vargas JH. (2004) Long-term parenteral nutritional support and 
intestinal adaptation in children with short bowel syndrome: a 25-yearexperience. J 
Pediatr. 145(2):57-63. 
107. Reber KM, Su BY, Clark KR, Pohlman DL, Miller CE & Nowicki PT. (2002) 
Developmental expression of eNOS in postnatal swine mesentery artery. Am J 
Physiol. 283: G1328–G1335.  
108. Reeds PJ, Hachey DL, Patterson BW, Motil KJ, Klein PD. (1992) VLDL 
apolipoprotein B-100, a potential indicator of the isotopic labelling of the hepatic 
protein synthetic precursor pool in humans: studies with multiple stable 
isotopically labeled amino acids. J Nutr. 122(3):457-66.  
109. Rispati G, Slaoui1 M, Weberl D, Salemink P, Berthoux C, Shrivastavai R. (1993) 
Haematological and plasma biochemical values for healthy yucatan micro pigs. 
Laboratory Animals 27:368-373.  
113 
 
110. Robert FP, Pencharz PB, Ball RO. (2000) Organ and Plasma Amino Acid 
Concentrations Are Profoundly Different in Piglets Fed Identical Diets via Gastric, 
Central Venous or Portal Venous Routes. J Nutr. 130: 1261–1266.  
111. Roberts SA, Ball RO, Moore AM. (1999) Tyrosine requirement in the parenterally 
fed neonate. FASEB J.  13:A910. 
112. Roberts SA, Ball RO, Moore AM, Filler RM, Pencharz PB. (2001) The effect of 
graded intake of glycyl-L-tyrosine on phenylalnine and tyrosine metabolism in 
parenterally fed neonates with an estimation of tyrosine requirement. Pediatr Res. 
49(1):111-9. 
113. Rombeau JL, Barot L R, Low DW, Twomey PL. (1984) Feeding by tube 
enterostomy. Clinical Nutrition Vol. 1 Enteral and Tube Feeding (RombeauJ. L. & 
Caldwell, M. D., eds.) 275–285. 
114. Rossi TM, Lee PC, Young C, and Tjota A. (1993) Small intestinal mucosa 
changes, including epithelial cell proliferative activity, of children receiving total 
parenteral nutrition (TPN). Dig Dis Sci. 38: 1608-1613.  
115. Siregar H, Chou CC. (1982) Relative contribution of fat, protein, carbohydrate, 
and ethanol to intestinal hyperemia. Am J Physiol. 242(1):G27-31. 
116. Shoveller AK, Brunton JA, House JD, Pencharz PB, Ball RO. (2003) Dietary 
cysteine reduces the methionine requirement by an equal proportion in both 
parenterally and enterally fed piglets. J Nutr. 133:4215–24. 
117. Shulman RJ, Henning SJ, Nichols BL. (1988) The miniature pig as an animal 
model for the study of intestinal enzyme development. Pediatr Res. 23(3):311-5. 
118. Shulman RJ. (1993) The piglet can be used to study the effects of parenteral and 
enteral nutrition on body composition. J Nutr. 123:395-8. 
119. Sparks HV. (1980) Effect of local metabolic factors on vascular smooth muscle. 
Handbook of Physiology. Sect. 2: The Cardiovascular System—Vascular Smooth 
Muscle. Am Physiol. Soc.Vol. II. 
120. Stoll B, Burrin DG, Henry J, Jahoor F, and Reeds PJ. (1997) Phenylalanine 
utilization by the gut and liver measured with inrtravenous and intragastric tracers 
in pigs. Am. J. Physiol. Gastrointest. Liver Physiol. 273:G1208–G1217. 
121. Stoll B, Henry J, Reeds PJ, et al. (1998a) Catabolism dominates first-pass 
metabolism of dietary essential amino acids in milk protein-fed piglets. J Nutr. 
128:606 - 614.  
122. Stoll B, Burrin DG, Henry J, Yu H, Jahoor F, Reeds PJ. (1998b) Dietary amino 
acids are the preferential source of hepatic protein synthesis in piglets. J Nutr. 
128:1517–24. 
123. Stoll B, Horst DA, Cui L, Chang X, Ellis KJ, Hadsell DL, Suryawan A, 
Kurundkar A, Maheshwari A, Davis TA, Burrin DG. (2010) Chronic parenteral 
nutrition induces hepatic inflammation, steatosis, and insulin resistance in neonatal 
pigs. J Nutr. 140(12):2193-200.  
124. Suryawan A, O'Connor PM, Bush JA, Nguyen HV, Davis TA. (2009) Differential 
regulation of protein synthesis by amino acids and insulin in peripheral and 
visceral tissues of neonatal pigs. Amino Acids. 37 (1):97-104.  
114 
 
125. Talbot RB, Swenson MJ. (1970) Blood volume of pigs from birth through 6 
weeks of age.Am J Physiol. 218(4):1141-4.  
126. Tomlinson C, Rafii M, Sgro M, Ball RO, Pencharz P. (2011a) Arginine is 
synthesized from proline, not glutamate, in enterally fed human preterm neonates. 
Pediatr Res. 69(1):46-50. 
127. Tomlinson C, Rafii M, Ball RO, Pencharz PB. (2011b) Arginine can be 
synthesized from enteral proline in healthy adult humans. J Nutr. 141(8):1432-6.  
128. Tomlinson C, Rafii M, Ball RO, Pencharz P. (2011c) Arginine synthesis from 
enteral glutamine in healthy adults in the fed state Am J PhysiolEndocrinolMetab. 
301(2):E267-73.  
129. Urschel KL, Shoveller AK, Pencharz PB, Ball RO. (2005) Arginine synthesis 
does not occur during first-pass hepatic metabolism in the neonatal piglet. Am J 
PhysiolEndocrinolMetab. 288: E1244–E1251. 
130. Urschel KL, Shoveller AK, Uwiera RR, Pencharz PB, Ball RO. (2006) Citrulline 
is an effective arginine precursor in enterally fed neonatal piglets. J Nutr. 
136:1806–13. 
131. Urschel KL, Evans AR, Wilkinson CW, Pencharz PB, Ball RO. (2007) 
Parenterally fed neonatal piglets have a low rate of endogenous arginine synthesis 
from circulating proline. J Nutr. 137:601–6  
132. Van Goudoever JB,Stoll B, Hartmann B, Holst JJ, Reeds PJ, Burrin DG. (2001) 
Secretion of trophic gut peptides is not different in bolus- and continuously fed 
piglets. J Nutr. 131(3):729-32. 
133. Wang H, Khaoustov VI, Krishnan B, Cai W, Stoll B, Burrin DG, Yoffe B. (2006) 
Total parenteral nutrition induces liver steatosis and apoptosis in neonatal piglets. J 
Nutr. 136(10):2547-52. 
134. White MF. (1985) The transport of cationic amino acids across the plasma 
membrane of mammalian cells. BiochimBiophysActa. 822(3-4):355-74. 
135. Widdowson EM, Southgate DA, T & Hey EN. (1979) Body composition of the 
fetus and infant. Nutrition and Metabolism of the Fetus and Infant. 169-177. 
136. Wilkinson DL, Bertolo RF, Brunton JA, Shoveller AK, Pencharz PB, Ball RO. 
(2004) Arginine synthesis is regulated by dietary arginine intake in the enterally 
fed neonatal piglet. Am J PhysiolEndocrinolMetab. 287: E454–E462. 
137. Williams HH, Curtin LV, Abraham J, Loosli JK, Maynard LA. (1954) Estimation 
of growth requirements for amino acids by assay of the carcass. J Biol Chem. 
208(1):277-86. 
138. Wu G, Borbolla AG, Knabe DA. (1994) The uptake of glutamine and release of 
arginine, citrulline and proline by the small intestine of developing pigs. J Nutr. 
124:2437–44. 
139. Wu G. (1998) Amino acid metabolism in the small intestine. Trends Comp 
Biochem Physiol. 4:39–74. 
140. Wu G, Flynn NE, Knabe DA. (2000) Enhanced intestinal synthesis of polyamines 
from proline in cortisol-treated piglets. Am J PhysiolEndocrinolMetab. 279 (2): 
E395-402. 
115 
 
141. Wu G, Meininger CJ. (2002) Regulation of nitric oxide synthesis by dietary 
factors. Annu Rev Nutr. 22:61–86.  
142. Wu G, Meininger CJ. (2009) Nitric oxide and vascular insulin resistance. 
Biofactors. 35:21–7. 
143. Wykes LJ, Ball RO, Menendez CE, Ginther DM, Pencharz PB. (1992) Glycine, 
leucine and phenylalanine flux in low-birth-weight infants during parenteral and 
enteral feeding. Am J ClinNutr. 55:971 
144. Wykes LJ, Ball RO, Pencharz PB. (1993) Development and validation of a total 
parenteral nutrition model in the neonatal piglet. J Nutr. 123(7):1248-59. 
145. Wykes LJ, House JD, Ball RO, Pencharz PB. (1994) Amino acid profile and 
aromatic amino acid concentration in total parenteral nutrition: effect on growth, 
protein metabolism and aromatic amino acid metabolism in the neonatal piglet. 
ClinSci (Lond). 87:75–84.  
146. Wyss M, Kaddurah-Daouk R. (2000) Creatine and creatinine metabolism. Physiol 
Rev.80:1107–213. 
147. Zamora SA, Amin HJ, McMillan DD, Kubes P, Fick GH, Bützner JD, Parsons 
HG, Scott RB. (1997) PlasmaL-arginine concentrations in premature infants with 
necrotizing enterocolitis. J Pediatr. 131(2):226-32. 
148. Zello GA, Wykes LJ, Ball RO, Pencharz PB. (1995) Recent advances in methods 
of assessing dietary amino acid requirements for adult humans. J Nutr. 
125(12):2907-15. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
116 
 
Appendix I. Plasma amino acid concentrations. 
 
 
IG-H Arg 
 
IG-L Arg 
 
IV-H Arg 
 
P-value 
 
SF Reference* 
 
Arginine family of Amino acid (µmol/L) 
Arginine 103  34ab 38  7a 133  37b 0.03 94 – 124 (109) 
Aspartate 14  5 17  6 15  5 0.7 11 – 19 (15) 
Citrulline 46  7 46  5 44  5 0.8 57 – 89 (73) 
Glutamine 104  24 132  5 128  26 0.2 202 – 240 (221) 
Glutamate 98  1 104  8 82  26 0.4 50 – 94 (72) 
Ornithine 102  10 57  15 116  32 0.06 54 – 80 (67) 
Proline 284  36 418  50 372  23 0.04 271 – 349 (310) 
Plasma Indispensable amino acid (µmol/L) 
Histidine 19  2a 28  2 43  8b 0.02 29 – 42 (36) 
Isoleucine 88  16a 114  9a 331  110b 0.02 76 – 122 (99) 
Leucine 160  33 209  11 162  17 0.09 137 – 183 (160) 
Lysine 287  32a 302  58a 412  44b 0.02 274 – 288 (281) 
Methionine 13  2 14  1 20  3 0.09 13 – 23 (18) 
Phenylalanine 157  33a 210  44a 834  161b 0.02 88 – 130 (109) 
Threonine 107  14 146  6 148  28 0.04 107 – 153 (130) 
Tryptophan 97  23 97  14 94  9 0.9 54 – 74 (64) 
Valine 168  25a 222  14a 616  203b 0.02 184 – 222 (203) 
Dispensable amino acid (µmol/L) 
Alanine 237  46 331  27 257  53 0.1 269 – 403 (336) 
Asparagine 14  5 17  6 15  5 0.7 9 – 19 (14) 
Glycine 360  33a 796  79b 372  28 <0.01 439 – 609 (524) 
Hydroxyproline 47  16 40  2 72  40 0.3 53 – 73 (63) 
Serine 141  12a 730  90b 166  22a <0.01 148 – 212 (180) 
Taurine 97  8a 143  13b 132  24ab 0.08 75 – 155 (115) 
Tyrosine 23  2a 58  7a 332  136b 0.02 78 – 116 (97) 
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Values are expressed as the mean ± SD using plasma amino acid concentrations from day 4, 5 & 6; n = 6 
(IG-H Arg and IG-L Arg) or 5 (IV-H Arg) per group. P values were determined by repeated measures 
ANOVA. Groups with differing superscripts are significantly different at P < 0.05 using Bonferroni’s 
multiple comparison tests. *SF Reference values (n = 3) presented as a range of mean ± SD, the group 
mean is presented in the bracket. 
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Appendix II.  Small intestinal mucosa free amino acid concentrations. 
 IG-H Arg 
 
IG-L Arg 
 
IV-H Arg 
 
P value SF Reference * 
 
Range * 
Arginine family of amino acid (µmol/g of tissue) 
Arginine 2.21  2.42 1.45  1.59 0.23  0.06 0.15 0.21 – 0.29 (0.25) 
Aspartate 0.92  0.29 0.81  0.15 0.89  0.28 0.87 0.72 – 1.10 (0.91) 
Citrulline 0.80  0.33 0.67  0.32 0.76  0.26 0.9 0.40 – 1.02 (0.71) 
Glutamine 0.24  0.09 0.28  0.09 0.25  0.10 0.77 0.19 – 0.61 (0.40) 
Glutamate 2.45  0.68 1.90  0.29 2.04  0.26 0.19 1.84 – 2.50 (2.17) 
Ornithine 0.37  0.31 0.26  0.20 0.17  0.03 0.3 0.15 – 0.23 (0.19) 
Proline 0.63  0.28 0.67  0.21 0.74  0.12 0.8 0.47 – 0.99 (0.73) 
Indispensable amino acid (µmol/ g of tissue) 
Histidine 0.09  0.02a 0.20  0.1b 0.14  0.06ab 0.04 0.09 – 0.15 (0.12) 
Isoleucine 0.26  0.05 0.27  0.07 0.53  0.41 0.09 0.14 – 0.34 (0.24) 
Leucine 0.37  0.15 0.50  0.27 0.32 .0.11 0.25 0.26 – 0.44 (0.35) 
 Lysine 0.62  0.27 0.53  0.20 0.59  0.15 0.35 0.32 – 0.56 (0.44) 
Methionine 0.80  0.25 0.67  0.26 0.86  0.18 0.7 0.50 – 1.14 (0.82) 
Phenylalanine 1.74  0.22a 1.67  0.29a 2.54  0.73b 0.01 1.45 – 1.91 (1.68) 
Threonine 0.32 .0.11 0.34  0.13 0.38  0.05 0.6 0.22 – 0.40 (0.31) 
Tryptophan 0.07  0.02 0.09  0.05 0.1  0.03 0.3 0.03 – 0.07 (0.05) 
Valine 0.47  0.16 0.60  0.28 1.0  0.9 0.1 0.36 – 0.58 (0.47) 
Dispensable amino acid (µmol/g of tissue) 
Alanine 1.32  0.44 1.71  0.8 1.37  0.19 0.35 1.17 – 2.35 (1.76) 
Glycine 2.91  0.95 3.36  0.47 2.54  0.51 0.18 2.85 – 3.83 (3.34) 
Hydroxyproline 0.10  0.06 0.09  0.04 0.08  0.03 0.9 0.01 – 0.15 (0.08) 
Serine 0.54  0.22a 1.33  0.23b 0.51  0.07a <0.0001 0.40 – 0.90 (0.65) 
Taurine 4.44  0.93 4.01  0.34 4.58  0.69 0.4 2.8 – 3.6 (3.20) 
Tyrosine 0.24  0.08 0.28  0.1 0.86  0.72 0.05 0.24 – 0.32 (0.28) 
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Values are means ± SD; n = 5 (IG-L Arg) or 6 per group. P values were determined by one-way ANOVA. 
Groups with differing superscripts are significantly different at P < 0.05 using Bonferroni’s multiple 
comparison test. *SF Reference values presented as a range of mean ± SD, the group mean is presented in 
the bracket. 
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Appendix III. Liver free amino acid concentrations. 
 
 
IG-H Arg 
 
IG-L Arg 
 
IV- H Arg 
 
P value SF Reference * 
Range* Arginine family of amino acids (µmol/g of tissue) 
Arginine 0.13  0.04ab 0.09  0.04a 0.17  0.02b 0.004 0.06 – 0.38(0.22) 
Aspartate 1.02  0.28 0.77  0.11 1.02  0.24 0.16 0.73 – 1.37(1.05) 
Citrulline 0.24  0.12 0.28  0.18 0.28  0.12 0.8 0.20 –  0.50(0.35) 
Glutamine 1.33  0.52 1.03  0.28 1.45  0.41 0.27 1.66 – 2.18(1.92) 
Glutamate 1.93  0.30 1.71  0.39 1.66  0.27 0.33 1.43 – 2.59(2.01) 
Ornithine 0.41  0.16 0.42  0.15 0.83  0.47 0.06 0.35 – 0.59(0.47) 
Proline 0.83  0.25a 1.11  0.33a 2.20  0.96b 0.005 0.76 – 1.04(0.90) 
Indispensable amino acids (µmol/g of tissue) 
Histidine 0.20  0.07 0.24  0.06 0.27  0.11 0.4 0.22 – 0.52(0.37) 
Isoleucine 0.24  0.05 0.24  0.05 0.52  0.44 0.14 0.22 – 0.50(0.36) 
Leucine 0.38  0.13 0.35  0.06 0.26  0.22 0.4 0.36 – 0.74(0.55) 
Lysine 0.50  0.35 0.27  0.23 0.67  0.47 0.2 0.01 – 0.05(0.03) 
Methionine 0.14  0.05 0.13  0.61 0.19  0.16 0.5 0.07 – 0.43(0.25) 
Phenylalanin
e 
1.78  0.39a 1.64  0.25a 2.77  0.91b 0.02 1.31 – 1.81(1.56) 
Threonine 0.28  0.08 0.23  0.02 0.30  0.09 0.22 0.27 – 0.47(0.37) 
Tryptophan 0.05  0.01 0.04  0.01 0.05  0.03 0.6 0.04 – 0.10(0.07) 
Valine 0.38  0.1 0.35  0.07 0.95  0.88 0.05 0.35  - 1.60(1.0) 
Dispensable amino acids (µmol/g of tissue) 
Alanine 
1.30  0.27 1.48  0.25 1.59  0.97 0.7 0.99 – 2.27(1.63) 
Glycine 3.62  0.51b 5.3  1.21a 3.12  0.52b 0.001 2.86 – 4.42(3.64) 
Hydroxyproli
ne 
0.16  0.03 0.12  0.01 0.13  0.06 0.3 0.17 – 0.27(0.22) 
Serine 1.93  0.22b 4.8  2.17a 2.01  0.33b 0.002 1.41 – 2.05(1.73) 
Taurine 6.28  1.25 5.43  1.44 4.02  1.75 0.06 6.95 – 9.45(8.20) 
Tyrosine 0.34  0.13 0.34  0.13 0.55  0.27 0.08 0.30 – 0.70(0.50) 
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Values are means ± SD; n = 5 (IG-L Arg) or 6 per group. P values were determined by one-way ANOVA. 
Groups with differing superscripts are significantly different at P < 0.05 using Bonferroni’s multiple 
comparison test. *SF Reference values presented as a range of mean ± SD, the group mean is presented in 
the bracket. 
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Appendix IV. Kidney free amino acid concentrations. 
 IG-H Arg 
 
IG-L Arg 
 
IV-H Arg 
 
P value SF Reference * 
Range* Arginine family of amino acids (µmol/g of tissue) 
Arginine 0.09  0.04 0.09  0.04 0.16  0.10 0.31 0.01 – 0.26 (0.14) 
Aspartate 1.00  0.15 0.97  0.24 0.98  0.12 0.8 0.95 – 1.31 (1.33) 
Citrulline 0.34  0.10 0.36  0.03 0.40  0.06 0.50 0.25 - 0.45 (0.35) 
Glutamine 0.40  0.14 0.50  0.10 0.30  0.04 0.07 0.58 - 0.88 (0.73) 
Glutamate 2.20  0.12 2.50  0.44 2.30  0.40 0.70 2.40 - 3.00 (270) 
Ornithine 0.33  0.05 0.30  0.08 0.50  0.11 0.045 0.17 - 0.49 (0.33) 
Proline 0.60  0.16a 0.70  0.02ab 0.90  0.05b 0.01 0.60 – 1.20 (0.90) 
Indispensable amino acids (µmol/g of tissue) 
Histidine 0.16 ± 0.02 0.18 ± 0.04 0.21 ± 0.06 0.3 0.16 - 0.32 (0.24) 
Isoleucine 0.44  0.14 0.32  0.04 0.43  0.21 0.56 0.35 - 0.51 (0.43) 
Leucine 0.47  0.09 0.48  0.06 0.42  0.14 0.74 0.36 - 0.6 (0.48) 
Lysine 0.44  0.15 0.37  0.05 0.60  0.30 0.28 0.20 - 0.60 (0.40) 
Methionine 0.21  0.03 0.21  0.03 0.21  0.03 0.97 0.17 - 0.29 (0.23) 
Phenylalanine 1.73  0.33 1.72  0.29 2.65  0.86 0.09 1.65 - 2.05 (1.85) 
Threonine 0.36  0.08 0.38  0.06 0.41  0.06 0.63 0.34 - 0.36 (0.35) 
Tryptophan 0.08  0.01 0.08  0.01 0.08 ± 0.03 0.98 0.06 - 0.08 (0.07) 
Valine 0.52  0.04 0.56  0.09 0.63  0.22 0.58 0.54 - 0.72 (0.63) 
Dispensable amino acids (µmol/g of tissue) 
 Alanine 1.23  0.28 1.61  0.32 1.37  0.06 0.19 1.40 - 2.20 (1.80) 
Glycine 3.23  0.76 4.23  0.96 3.37  0.83 0.31 4.55 - 4.95 (4.75) 
Hydroxyproline 0.07  0.02 0.08  0.02 0.08  0.02 0.77 0.08 - 0.1 (0.09) 
Serine 0.72  0.14a 1.70  0.57b 0.68  0.06a 0.005 0.52 - 0.84 (0.68) 
Taurine 6.6  0.73 5.9  1.3 5.3  1.9 0.50 3.60 - 5.40 (4.50) 
Tyrosine 0.25  0.1 0.3  0.06 0.99  1.22 0.29 0.24 - 0.44 (0.34) 
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Values are means ± SD; n = 3 (IG-L Arg) or 4 per group. P values were determined by one-way ANOVA. 
Groups with differing superscripts are significantly different at P < 0.05 using Bonferroni’s multiple 
comparison test. *SF Reference values presented as a range of mean ± SD, the group mean is presented in 
the bracket. 
